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Summary 
	 Diseases caused by viral infections are major concerns for human being. Viruses like 
human immunodeficiency virus (HIV), hepatitis B virus (HBV) and hepatitis C virus (HCV) 
that induce chronic infection, is always a risk for human life. Understanding the mechanisms 
how immune system combat against viral infection can help to develop better vaccines or 
treatment therapies to prevent from lethal viral infections.  
Here in this study, we analyzed the roles of CD169+ macrophages present in splenic 
marginal zone on adaptive immunity. Initial virus replication in splenic CD169+ macrophages 
during systemic infection of vesicular stomatitis virus (VSV) was described earlier which 
activate innate and adaptive immune system. Here using Lymphocytic choriomeningitis virus 
(LCMV) in mouse model, we found that CD169+ macrophages in spleen and lymph node 
produce type I interferon (IFN-I). IFN-I acts as antiviral and inhibited virus replication in 
different peripheral organs, and stimulated program death ligand 1 (PD-L1) expression in 
liver. PD-L1 is a ligand for PD-1 expressed on activated CD8+ T cells, and PD-L1/PD-1 axis 
signaling induces CD8+ T cell exhaustion. In absence of CD169+ macrophages, IFN-I 
production was impaired and PD-L1 expression was highly reduced. This led to 
overwhelming virus replication in absence of CD8+ T cells exhaustion that resulted in severe 
immunopathology and death of mice. This study clearly shows the role of CD169+ 
macrophages in regulating the functions of CD8+ T cells. 
In another study, we described the influence of virus-specific antibodies or virus-specific 
memory CD8+ T cells on splenic CD169+ macrophages during systemic recall infection of 
LCMV. We reported that the presence of LCMV-specific antibodies permit intracellular viral 
replication in CD169+ macrophages of splenic marginal zone but suppressed viral replication 
in peripheral organs. During persistent infection with the LCMV-Docile, viral replication in 
CD169+ macrophages of spleen in presence of virus specific antibodies was found to be 
essential for priming of CD8+ T cells that led to viral clearance. In parallel to specific 
antibodies, memory CD8+ T cells inhibited viral replication in CD169+ macrophages and 
systemic IFN-I production, and failed to mount effective CD8+ T cell response that resulted in 
viral persistence. This investigation explains the mechanism of immune activation and 
protection in presence of virus specific antibodies during secondary viral infection. 
Over all from these two studies we can conclude that CD169+ macrophages play 
significant roles for inducing strong antiviral innate and adaptive immunity during primary 
and secondary viral infection.  
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Zusammenfassung 
 Krankheiten, die durch Virusinfektionen ausgelöst werden, stellen eine große 
Besorgnis für die Menschheit dar. Viren wie das humane Immundefizienz-Virus (HIV), 
Hepatitis B Virus (HBV) und Hepatitis C Virus (HCV), die chronische Infektionen 
verursachen, sind immer lebensbedrohlich. Die Mechanismen zu verstehen, wie das 
Immunsystem Virusinfektionen bekämpft, kann helfen bessere Impfstoffe oder Therapien zu 
entwickeln, um tödlichen Virusinfektionen vorzubeugen. 
 In dieser Studie untersuchten wir die Rolle von CD169+ Makrophagen, die in der 
Marginalzone der Milz lokalisiert sind, für der adaptiven Immunantwort. Die anfängliche 
Virus-Replikation in den CD169+ Makrophagen der Milz bei einer systemischen Infektion mit 
dem vesikulären Stomatitis-Virus (VSV), welche das angeborene und adaptive Immunsystem 
aktiviert, wurde bereits beschrieben. Indem wir hier das lymphozytäre Choriomeningitis-
Virus (LCMV) im Maus-Modell untersuchten, fanden wir, dass die CD169+ Makrophagen in 
Milz und Lymphknoten Typ-I-Interferon (IFN-I) produzieren. IFN-I agierte antiviral, 
inhibierte somit die Virus-Replikation in verschiedenen peripheren Organen und stimulierte 
die Expression von program death ligand 1 (PD-L1) in der Leber. PD-L1 ist ein Ligand für 
PD1, das auf aktivierten CD8+ T-Zellen exprimiert wird. Die Signale über die PD-L1/PD1-
Achse induzieren die Erschöpfung von CD8+ T-Zellen.  In Abwesenheit von CD169+ 
Makrophagen war die IFN-I-Produktion und PD-L1-Expression stark reduziert. Die führte zu 
einer überwältigenden Virus-Replikation bei fehlender CD8+ T-Zell-Erschöpfung, was in 
schwerer Immunpathologie und dem Tod der Mäuse endete. Diese Arbeit zeigt klar die Rolle 
von CD169+ Makrophagen bei der funktionalen Regulierung der CD8+ T-Zellen auf. 
 In einer zweiten Studie beschrieben wir den Einfluss Virus-spezifischer Antikörper 
oder Virus-spezifischer CD8+ T-Zellen auf die CD169+ Makrophagen der Milz während einer 
systemischen Zweit-Infektion mit LCMV. Wir berichteten, dass die Anwesenheit von LCMV-
spezifischen Antikörpern die intrazelluläre Virus-Replikation in den CD169+ Makrophagen 
der Marginalzone der Milz zulässt, aber die Virus-Replikation in peripheren Organen 
unterdrückt. Während einer persistenten Infektion mit LCMV-Docile war die Replikation in 
den CD169+ Makrophagen der Milz bei Anwesenheit Virus-spezifischer Antikörper essentiell 
für die Vorbereitung der CD8+ T-Zellen, was zur Beseitung des Virus führte. Parallel zu 
spezifischen Antikörpern inhibierten CD8+ T-Gedächtnis-Zellen die Virus-Replikation in 
CD169+ Makrophagen und die systemische IFN-I-Produktion und schafften es nicht eine 
effective CD8+ T-Zell-Antwort aufzubauen, was in der Persistenz des Virus resultierte. Diese 
Untersuchung erklärt die Mechanismen der Immun-Aktivierung und des Immun-Schutzes bei 
Anwesenheit von Virus-spezifischen Antikörpern bei viralen Zweit-Infektionen.  
Insgesamt kann man aus diesen beiden Studien schlussfolgern, dass CD169+ 
Makrophagen signifikante Rollen für die Induzierung einer starken antiviralen angeborenen 
und adaptiven Immunantwort bei viralen Erst- und Zweit-Infektionen einnehmen. 
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1.1 Immune System 
The immune system is a defense machinery of multicellular organisms to protect them 
from harmful invaders like viruses, bacteria, fungus and parasites. The mammalian immune 
system is highly evolved and consists of three different layers of host defense includes 
physical barrier, innate immunity and adaptive immunity1 (Fig.1.1). Physical barriers act as 
first line of defense include skin, mucus layer in airway and intestine, low stomach pH and 
lysozymes in tear and saliva1-3. If physical barrier is breached by pathogens then innate 
immune system comes in to play that includes phagocytic cells like granulocytes, 
macrophages and dendritic cells4. These innate immune cells engulf, digest and process 
pathogens and present antigens to adaptive immune system cells like B cells and T cells to 
mount a highly specific immune response against them5. Because of specific adaptive 
immune response, host get rid of pathogens and memorize this identity to response fast and 
aggressively if same pathogen attacks the host in future6 (Fig. 1.1). 							 
 
                Figure 1.1: Components of immune system  
Turvey S.E; et al. J Allergy Clin Immunol. Feb. 2010 (modified) 
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1.1.1 Structure of Immune System 
The immune system of mammals is composed of complete organs, lymphatic vessels, 
cells and proteins2,3. On the basis of development and performing of immune response, there 
are three main organs of immune system including primary, secondary and tertiary lymphoid 
organs2,3,7,8. Primary lymphoid organs include bone marrow and thymus, mainly responsible 
for development of all immune cells from hematopoietic stem cells, process known as 
Haematopoiesis3,9 (Fig. 1.2). Secondary lymphoid organs provide a proper microenvironment 
to initiate effective immune response against pathogens3,9.  
	
	
	
	
	
	
	
	
	
	
	
	
Spleen, lymph nodes (LNs) and mucosal associated lymphoid tissue (MALT) are part of 
secondary lymphoid organs8. Immune cells primed and matured upon antigen encounter to 
become effector cells in secondary lymphoid organs, when these cells return to site of 
infection and reside there as memory cells form a tertiary lymphoid structure3,8. Lymph nodes 
                  Figure 1.2: Haematopoiesis 
Kindt TJ, et al Kuby immunology (2007), (6th ed.)  
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are present all over in mammalian body collecting antigens from peripheral tissues and 
specialized to provide environment for mounting immune response against pathogens3. There 
is only one spleen in mammalian body which is specialized to filter pathogens entering in 
blood circulation3.  For this study, we mainly focus on structure of the spleen. 
1.1.1a Spleen 
The spleen is a well-structured oval shaped capsule contains two main compartments, the 
red pulp and white pulp which are separated by specialized region called as marginal zone 
(MZ)3,10,11 (Fig 1.3).  The red pulp is comprised of network of sinuses populated by red blood 
cells (RBCs), red pulp macrophages and some lymphocytes as well. Splenic red pulp 
macrophages engulf and degrade old and defective RBCs. The red pulp apart from immune 
functions is also involved in iron metabolism, thrombocytes (platelets) storage and 
haematopoiesis3,10.  
 
The white pulp made-up of T cell and B cell zones. T cell zone is also known as the 
periarteriolar lymphoid sheath (PALS) contains networks of fibroblastic reticular cells (FRCs) 
adjoining by central arteriole. B cell zone contains B cells follicles and a central network of 
follicular dendritic cells (FDCs)10,11 (Fig 1.3).  
The splenic marginal zone (MZ) surrounding the white pulp is in direct contact with white 
pulp B cells. MZ contains two sunsets of macrophages. The outer layer of marginal zone 
		 	 	          Figure 1.3: Structure of spleen  
   Kindt T. J; et al (2007), Kuby immunology (6th ed.)                                   
                 Mueller S.N; et al. Nat Rev Immunol. 2009 (modified) 
Nature Reviews | Immunology
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Peyer’s patches
Groups of lymphoid nodules 
present in the small intestine 
(usually the ileum). They occur 
massed together on the 
intestinal wall, opposite the 
line of attachment of the 
mesentery. Peyer’s patches 
consist of a dome area, B cell 
follicles and interfollicular T cell 
zones. High endothelial venules 
are present mainly in the 
interfollicular areas.
High endothelial venule
(HEV). A specialized venule that 
occurs in secondary lymphoid 
organs, except the spleen. HEVs 
allow continuous transmigration 
of lymphocytes as a 
consequence of the constitutive 
expression of adhesion 
molecules and chemokines  
at their luminal surface.
Stromal subsets in SLOs
The non-haematopoietic cell types in the spleen and 
lymph nodes can be divided into at least seven subsets 
on the basis of their location, function and phenotype 
(TABLE 1; see Supplementary information S2 (table)). 
Here we focus on the stromal cell subsets that make up 
the parenchyma of SLOs, including FRCs, FDCs, MRCs, 
splenic red pulp fibroblasts and lymph node medul-
lary fibroblasts, rather than the vascular endothelial 
cells and lymphatic endothelial cells that are involved 
in blood and lymph flow through SLOs (reviewed in 
REFS 16,21). In this section, we describe some of the 
known phenotypes of the heterogeneous stromal cell 
populations and their topological organization in SLOs. 
In subsequent sections, we describe the functions of the 
lymphoid stromal cells, in particular FRCs.
FRCs. Reticular networks have been observed in tissues 
such as lymph nodes for more than 100 years (cited in 
REF. 22), although the cellular components of these net-
works only began to be characterized in the 1960s13,23,24. 
It was initially assumed that the role of FRCs in lym-
phoid organs was mainly structural, possibly to assist 
in the expansion and contraction of the lymph nodes 
during immune responses and to facilitate antigen or 
antibody transport. Subsequently, Anderson and Shaw25 
proposed that the transport of cytokines from the affer-
ent lymph to HEVs involved conduits formed by FRCs. 
This was then directly shown in the lymph nodes26 and 
spleen27, heralding a new appreciation of the functions 
of the lymphoid stroma.
The FRCs in the T cell zones of the spleen and lymph 
nodes surround the central arterioles and HEVs, respec-
tively, forming a dense network filled with lymphocytes25. 
We now know from live imaging studies using two-
photon laser scanning microscopy that lymphocytes in 
these regions are in constant dynamic motion and that 
they move along FRC strands that function as guidance 
paths for cell migration28. FRCs produce and surround 
the collagen-rich reticular fibres, forming an enclosed 
conduit structure that is separate and distinct from the 
parenchyma of the lymphoid tissue (FIG. 3). Small mol-
ecules, such as chemokines and antigens, can enter the 
conduit network in lymph nodes from the lymph and are 
delivered rapidly to T cell zones and HEVs26. Molecules of 
high molecular mass cannot enter the conduit lumen and 
instead are trapped by SCS macrophages and accumulate 
in the cortical sinuses or continue around the SCS and 
drain through efferent lymphatic vessels. Such functional 
exclusion of large molecules and particles could restrict 
the types of signal delivered by the FRC conduits and pre-
vent their exploitation by pathogens. In the spleen, FRCs 
in the T cell zones also collect blood-borne molecules in 
conduit structures27. Interestingly, molecular exclusion 
apparently differs in the spleen, as 70 kDa dextran enters 
the splenic conduits27 but is excluded from lymph node 
conduits26. This raises the possibility that the system is 
tuned to allow delivery of distinct signals through the 
conduit networks in the T cell zones of different SLOs.
The reticular fibres in the T cell zones are rich in 
collagen, and the surrounding FRCs produce tis-
sue transglutaminase and other molecules that are 
Figure 1 | Organized architecture of the spleen. a | Schematic representation of the organization of the spleen.  
The white pulp consists of T cell zones (also known as the periarteriolar lymphoid sheath), which contain networks of 
fibroblastic reticular cells (FRCs) surrounding a central arteriole, and B cell follicles, which contain a central network of 
follicular dendritic cells (FDCs). The marginal zone surrounding the white pulp contains marginal reticular cells (MRCs), 
particularly at the edges of the B cell follicles. Blood and leukocytes entering the spleen pass through branches of the central 
arteriole, which end in the marginal sinuses and red pulp. In the cords of the red pulp, a dense network of reticular fibroblasts 
and fibres construct an open blood network, which is marked by its lack of a typical endothelial cell lining. Large numbers of 
macrophages phagocytose dying or damaged red blood cells in the red pulp (not shown). Immune cells enter the white pulp 
at regions where the T cell zones are adjacent to the marginal zone, which are known as the marginal zone bridging channels. 
b | An image of a section of mouse spleen generated using multi-colour immunofluoresence microscopy. This illustrates the 
organization of the white pulp, red pulp and marginal zone. The distribution of CD3+ T cells (white), B220+ B cells (blue), CD169+ 
marginal zone macrophages (cyan), CD11c+ DCs (green) and ER-TR7+ stromal cells (red) is shown. c | The distinct organization 
of str mal cells in differen  regions of the spleen is shown by single-colour immunofluoresence staining with ER-TR7. 
Networks of stromal cells and reticular fibres form in the white pulp, including FRCs in T cell zones, FDCs in B cell follicles 
(ER-TR7–) and MRCs in the marginal zone. A dense network of stromal cells and reticular fibres is present in the red pulp.
REVIEWS
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contains marginal zone (MZ) macrophages are identified by expression of SIGN-R1 and 
MARCO markers (Fig. 1.4). The macrophages in inner layer of MZ are classified by 
expression of SINGLEC1/CD169 marker and known as metallophilic or marginal zone 
metallophilic macrophages10-12. There are also two subsets of other cells, the marginal zone B 
cells and DCs located in between these two layers of MZ macrophages13 (Fig. 1.4). 
 
Blood circulation in spleen- Spleen receives blood from splenic artery which branches into 
central arterioles that are surrounded by PALS. Central arterioles further branch into smaller 
follicular arterioles, which cross follicles, and penicillar arterioles that cross end in marginal 
sinus or connected to red pulp vein10,14 (Fig. 1.5). The blood in the marginal sinus drains into 
the splenic cords and then to sinuses of the red pulp makes an open circulation system. When 
blood from penicillar arteriole flowing directly to sinus, this makes closed circulation in 
spleen10,14.      
During systemic infection, pathogens or cells carrying the pathogens or other immune cells 
enter spleen by splenic artery and make initial interaction with MZ cells in marginal sinus 
(Fig. 1.5). The blood in the marginal sinus flows slowly and the cells of MZ like marginal 
zone macrophages, metallophilic macrophages, MZ B-cells and dendritic cells get enough 
Figure 1.4: Marginal zone macrophages 
				Davies LC, et al. Nat Immunol. 2013  
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time to trap the antigens13. After binding with antigens, DCs migrate to T cell area and lead to 
antigen specific T-cell response. B-cells that bind to its specific antigen, migrate to follicles 
and generate germinal center and produce antigen specific antibodies15,16.  
 
1.1.2  Innate immune system 
 Innate immune system induces non-specific immediate immune response upon entry 
of pathogens to host body. Innate immune cells recognize specific pattern of molecules 
present on pathogens called as pathogen-associated molecular patterns (PAMPs), mediated by 
pattern-recognition receptors (PRRs) on innate immune cells4,5. Due to this interaction of 
pathogens, immune cells get activated and produce several soluble proteins like cytokines and 
chemokines, which further inhibit pathogens and alert other cells. Innate immune system 
comprises granulocytes, dendritic cells (DCs), monocytes, macrophages, NK cells and 
complement molecules3. Here we want to focus on DCs and specially on macrophages.  
1.1.2a  Dendritic Cells 	
	  DCs develop from lymphoid and myeloid progenitors (Fig. 1.1), and are present at 
possible entry sites for pathogens like skin, mucosal tissues and in most of lymphoid and 
non-lymphoid organs3,17. DCs upon pathogen encounter promote both pro-inflammatory 
				Figure 1.5: Blood circulation in spleen 
     Junqueira’s Basic Histology Text & Atlas (12th ed.) (modified)        
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and anti-inflammatory immune responses17-19. DCs are professional antigen-presenting cells 
and their main function is to process and present antigen to T cells of adaptive immune 
system to stimulate specific immunity to foreign antigens and tolerance to self-antigens17-
19. The surface phenotypic markers expressed by almost all type of DCs are CD45, CD11c 
and MHCII17. There are two main types of DCs depending upon their location and functions, 
plasmacytoid DCs (pDCs) and conventional or classical DCs (cDCs)17. cDCs are very 
efficient in antigen processing and presentation to T cells. pDCs are mainly present in 
circulation and SLOs, express high level of TLR7 and TLR9, and are main producers of  IFN-
I upon viral infection20.  
1.1.2b 	 Macrophages	
Macrophages are located throughout the body in lymphoid and non-lymphoid organs, and 
are professional phagocytic innate immune cells. These cells engulf all kind of particles or 
cells including microbes or cancer cell which do not resemble to be a part of healthy body21,22. 
Before it was shown that macrophages develop from circulatory blood monocytes during 
steady state and inflammation in different tissues23. But recent studies showed that 
macrophages are derived from embryonic precursors and maintain them by self-renewal24. 
Macrophages are present in most of organs and got their name according to their location 
(shown in Fig. 1.6). In mice, all tissue resident macrophages can be identified by surface 
expression of F4/8012. There are some other cells types beside tissue resident macrophages 
that are present in lymphoid tissues and identified by different marker like SIGNR1 and 
CD169. Cells that express CD169 marker on cell surface are metallophilic macrophage in MZ 
of spleen, subcapsular sinus and medullary sinus macrophages in lymph nodes, and specific 
subsets of tissue resident macrophage25. Here we will discuss more about splenic 
metallophilic macrophages and liver macrophages.  
the expression of cell-surface markers. Inflammatory 
monocytes in mice are defined as CCR2+ (CC-chemokine 
receptor 2), CX3CR1low (CX3C-chemokine receptor 1) 
and GR1+ (also known as Ly6), whereas resident mono-
cytes are defined as CCR2–CX3CR1hiGR1– (REF. 14). The 
extrapolation of data from mice to humans becomes 
confusing because human monocytes, which can also 
be separated into two general categories based on their 
expression of cell-surface markers, seem to have distinct 
physiology from that of mouse monocytes15. In humans, 
most monocytes are CD14hiCD16– and are referred to 
as ‘classical’ monocytes16, or are CD14+CD16+ and are 
referred to as ‘non-classical’ monocytes16. Approximately 
90% of human monocytes express the classical markers, 
whereas in mice the two populations of monocytes are 
approximately equally represented in the blood16.
In mice, the first monocytes that enter the blood-
stream from the bone marrow are thought to have an 
inflammatory phenotype16. These cells then rapidly exit 
the bloodstream and develop into tissue macrophages 
or DCs17. One theory holds that monocytes that are not 
initially recruited to the tissue can further mature in the 
blood and eventually become part of a blood-resident 
population of monocytes that is thought to contribute to 
the integrity of the endothelial-cell lining of blood ves-
sels and the maintenance of tissue-resident macrophage 
populations in the steady state18. Furthermore, these cells 
become the main source of inflammatory macrophages 
in tissues during inflammation and trauma, in which 
the migration of monocytes from the bloodstream is 
dramatically enhanced.
Although it is well-accepted that monocytes can 
replenish tissue-macrophage numbers, especially during 
inflammation, there are cases in which local proliferation 
of tissue-resident colony-forming cells can directly give 
rise to populations of mature macrophages in the tissue. 
The best example of this local proliferation might be the 
microglial cells of the central nervous system19. Several 
unresolved questions regarding monocyte heterogeneity 
remain, such as whether discrete monocyte populations 
give rise to specific macrophage populations in the tis-
sue and whether alterations in monocyte markers can 
be exploited to diagnose diseases or to analyse disease 
resolution following treatment.
Macrophage populations
Macrophages can respond to endogenous stimuli that 
are rapidly generated following injury or infection. 
These early stimuli are typically produced by innate 
immune cells and can exert a marked, though usually 
transient, effect on the physiology of macrophages. 
Macrophages can also respond to signals that are 
produced by antigen-specific immune cells. These 
signals are more focused and prolonged than innate 
immune stimuli and generally give rise to longer-term 
alterations in macrophages20. To complicate matters, 
macrophages themselves can produce several factors 
that influence their own physiology. In the next sec-
tion, we describe three populations of activated macro-
phage, each of which has a distinct physiology (FIG. 3). 
We propose that these populations can be generated in 
response to either innate or adaptive immune signals. 
Nature Reviews | Immunology
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Figure 2 | Monocyte heterogeneity. Monocytes originate in the bone marrow from a common haematopoietic stem cell 
(HSC). They undergo differentiation steps during which they commit to the myeloid and then to a monocyte lineage. In 
response to macrophage colony-stimulating factor, they divide and differentiate into monoblasts and then pro-monocytes 
before becoming monocytes, which exit the bone marrow and enter the bloodstream. In mice, there is evidence of two 
distinct monocyte populations in the blood that have different phenotypes and biochemical signatures. GR1+CX
3
CR1low 
(CX
3
C-chemokine receptor 1) monocytes rapidly exit the blood, and for this reason they are referred to as ‘inflammatory’ 
monocytes. GR1–  monocytes have been termed ‘resident’ monocytes to differentiate them from the other population. It 
remains unknown whether inflammatory monocytes mature into resident monocytes in the blood or whether these two 
cells represent distinct monocyte populations. Human monocytes can also be divided into two populations, but the 
designations inflammatory and resident do not apply to these populations. Monocytes migrate to different tissues, where 
they replenish tissue-specific macrophages. CNS, central nervous system; GM-CFU, granulocyte/macrophage 
colony-forming unit; M-CFU, macrophage colony-forming unit.
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1.1.2b1  Metallophilic macrophages/MZ CD169+ macrophages 
Metallophilic macrophages also known as marginal zone metallophilic macrophages are 
present in marginal zone of spleen (Fig. 1.4). These cells express CD169 (sialoadhesin or 
siglec-1; sialic acid binding Ig-like lectin-1) protein on cell surface10,12. Presence of B-cells or 
lymphotoxin signaling is crucial for development of metallophilic macrophages26,27. During 
systemic infection metallophilic macrophages capture pathogen flowing in MZ sinus and 
mount initial immune response. Recently it was described that these cells lack sufficient 
interferon signaling and experience enhanced virus replication during initial virus infection 
phase28. Studies showed that metallophilic macrophages produce type-I interferon after viral29 
and bacterial infection30.  Targeting of antigen to metallophilic macrophages appears to 
facilitate the generation of cytotoxic T cells after transfer of blood-borne antigen31. 
1.1.2b2 Liver macrophage	
Liver macrophages were first discovered by Karl Wilhelm von Kupffer in 1876, hence 
also known as Kupffer cells (KCs)32. KCs are seeded along sinusoidal endothelial cells all 
over liver (Fig. 1.7) and making largest population of macrophages among all solid 
tissues32,33.  KCs present promote tissue integrity upon liver injury or infection by maintaining 
homeostasis, immunological tolerance, filtering all entering microbes via blood and initiation 
or suppressing immune responses34-36. KCs also contribute to progression of liver disease like 
hepatitis, fibrosis and cancer34-36. KCs originate from erythromyeloid progenitors derived 
from the embryonic yolk sac and/or fetal liver37-39. KCs are capable of self-replication during 
homeostasis and after liver injury37,38. Mouse Kupffer cells are characterized by their F4/80, 
CD11b+/low, CD68 and C-type lectin domain family 4-member F (CLEC4F) surface 
phenotype39-41.   
  Figure 1.7: Kupffer Cells in hepatic microenvironment  
       Crispe IN. Nature Reviews Immunology, 2013  
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KCs show antiviral roles early after infection in IFN-I dependent manner42. Hepatitis B virus 
(HBV) and Hepatitis C virus (HCV) bind to KCs and activate them to inhibit virus 
replication43-45. KCs express programmed cell death ligand (PD-L1) and secret IL-10, 
transforming growth factor beta 1 (TGF-β1) and prostaglandin E2 (PGE2) and thereby down 
regulate T cell functions during virus infection46-48.  
1.1.2c Interferons	
Interferons (IFNs) are secreted cytokines and have diverse effect on different cell types. 
They are grouped in to three classes called type I, II and III IFNs49. IFN-I include IFNa and 
IFNb, and usually almost all cells in body can produce IFN-I upon stimulation of PRRs by 
PAMPs50. PRRs are toll like receptors (TLRs) or other receptors present on cell surface as 
well as in inside the cell, and can detect nucleic acid or other surface moieties of pathogens. 
IFN-I have diverse effects on innate and adaptive immune cells. IFN-I signaling via its 
receptor induces antiviral mechanisms and inhibit host cell proliferation3. IFN-I enhance 
antiviral functions of B and T cells50. IFN-I have been shown to cause immunopathology in 
influenza virus infection51. They can lead to immunosuppression during chronic viral 
infections, such as LCMV52. During bacterial infections, low levels of type I IFNs required to 
initiate cell-mediated immune responses50. 
IFN-II known as interferon-g is produced by activated T and NK cells. IFN-II bias T cell help 
toward TH1 type, and activate and enhance macrophages functions53. IFN-I and II are known 
to enhance antigen presentation54,55. IFN-III is interferon-l and there are three members of 
this group named IFN-l1(IL-29), IFN-l2(IL-28A), and IFN-l3(IL-28B)56. IFN-III like type 
IFN-I upregulate the expression of genes that control viral replication and host cell 
proliferation56.  
1.1.3	 Adaptive immune system	
	 Innate immune cells process and present pathogen moieties to adaptive immune 
system, which induces highly pathogen-specific immune response. It is mediated by T cells 
and B cells, and always leads to immunological memory that is a hallmark of adaptive 
immune system2,3. T cells and B cells are two main cell types of adaptive immune system and 
key parts of cellular and humoral immunity respectively.  
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1.1.3a T cells 
 T cells or T lymphocytes get their name as ‘T’ because these cells originate in bone 
marrow and get mature in thymus (T). T cells play central role in cell-mediated immunity and 
can be recognized by their T-cell receptor (TCR) expression on cell surface57. T cells develop 
from T-cell progenitor cells in thymus on the basis of their TCRs reactivity to complex of self 
peptides and major histocompatibility complex (MHC) molecules on surface of thymic 
epithelial cells57. This process undergoes different stages and produce mature CD4+ T cells 
and CD8+ T cells and these cells then migrate to SLOs.  
1.1.3a1 T cell activation 
 Once APCs mainly DCs engulf pathogens or have been infected by pathogens, get 
activated via PRRs and migrate to LN or spleen58. DCs enter T cell zone and present antigen 
Signal	1
Signal	2
Signal	3
Several	divisions
T	cell
																																	Figure 1.8: T cell activation 
      Owen	JA,	et	all.	Kuby	Immunology,	7th	edition,	2013 (modified) 
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in complex with MHC molecule to naïve T cells. For the activation of naïve T cells mainly 
three signals are required59,60. Signal 1 is TCR/MHC-peptide along with CD4 and CD8 
coreceptors. Signal 2 is costimulation by CD28 (expressed on T cells) with CD80 or CD86 
(expressed on APCs). Signal 1 and 2 initiate activation of transcription factors that induce IL-
2 receptors expression and IL-2 release from T cells. IL-2 (can also be generated from helper 
T cells) is signal 3 and act in autocrine (stimulate same cells) or paracrine (stimulate nearby 
cells) manner. Signal 1 and 2 along with 3 lead to T cell proliferation and differentiation in to 
effector or memory cells59-61 (Fig. 1.8).		
1.1.3a2 Effector T cells 
 CD8+ T cells that interact with antigen in complex with MHC class I via TCR lead to 
proliferation and differentiate in to effector CD8+ T cells or cytotoxic T cell/lymphocytes (TC  
cells or CTL)58. In the same way CD4+ T cells interact with antigen in complex with MHC 
class II undergo proliferation and differentiation in to effector helper T cell58 (TH cells). 
CTLs leave SLOs and circulate to site of infection where they attack target cells (pathogen 
infected cell). A CTL binds to target cell by recognizing antigen from pathogens bound to 
MHC class I expressed by infected cells that lead to formation of highly organized 
immunological synapse (Fig. 1.9)3. This immunological synapse is more supported by 
adhesion molecules expressed by CTL and target cell and bring them very close together. 
    Figure 1.9: Cytotoxic T lymphocyte mediated killing 
           Owen JA, et all. Kuby Immunology, 7th edition, 2013 
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CTL have large granules filled with perforin and granzymes molecules and after conjugation 
with target cell these granules migrate to site of interaction and released in to space between 
two cells (Fig. 1.9). Perforin molecules create pore in target cell and granyzme molecules 
enter cell via these pores or by endocytosis that trigger apoptosis in target cell (Fig. 1.9)3,62. 
CTLs can also induces apoptosis in target cells by Fas-FasL interactions. FasL expressed on 
CTLs and trigger death signal via its natural receptor Fas expressed by target cells3,62.  
On the other hand, effector CD4+ T cells or TH cells secret cytokines that regulate functions of 
different cell types including B cells, macrophages and other T cells3. At the site of infection, 
TH cells secrets cytokines that enhance activity of macrophages and CTLs.  
Naïve CD4+ T cells that are primed and activated in presence of different cytokines 
produced by APCs or other immune cells, become polarised and differentiate in to diverse 
effector helper T cells and regulate different immune functions63. There are several subsets of 
effector helper T cells with their different functions are described in figure 1.10. 
Figure 1.10: T helper subsets differentiation and functions 
        Swain SL, et al. Nature Reviews Immunology, 2012 
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1.1.3a3 Memory T cells 
Once pathogen is eliminated, almost 90% of effector T cells die and leaving behind a 
small population of antigen specific memory T cells. Memory T cells are long lived and very 
sensitive cells that mount fast, robust and more effective secondary immune response with 
minimal symptoms upon antigen re-encounter3,64. Naïve T cells are mostly activated by DCs 
but memory T cells can be activated by macrophages, DCs and B. cells. There are two known 
subsets of memory T cells on the basis of their location, surface expression of markers (Fig. 
1.11) and to some extent their functions3,64. One is central memory T cells that reside in SLOs 
and other is effector memory T cells which reside mainly in peripheral tissues. Surface 
expression molecules of memory cells in relation to naïve and effector T cells are shown in 
Figure 1.11. 
	
	
	
	
	
 
1.1.3a4 Exhausted T cells 
Exhausted T cells are dysfunctional effector T cells that result during chronic infection or 
cancer. During persistent infection with constant antigen signaling via TCRs, exhaustion can 
occur by 3 different negatively regulatory pathways52,65 that include cell surface inhibitory 
receptors66 (iRs) (such as PD-1, CTLA-4, Tim3 and many more) on T cells, inhibitory 
cytokines and immunoregulatory cell types. iRs are highly expressed on effector T cells and 
down regulated on memory T cells upon pathogens elimination but prolonged and high 
expression of multiple iRs is a key feature of T cell exhaustion66 (Fig. 1.12). One of the well-
known inhibitory receptor on activated effector T cells is PD-1. iR ligand (iRL) for  PD-1 are 
PD-L1 expressed more broadly on non-hematopoietic cells in different tissues like SLOs, 
liver, lung and also on tumor cells; and PD-L2 expressed mainly on APCs67. Blocking of PD- 
 
Figure 1.11: Surface expression markers of T cell subsets 
Owen JA, et all. Kuby Immunology, 7th edition, 2013 
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1 pathway during chronic infection lead to rescue of T cells exhaustion68. There are some 
immunoregulatory cytokines which induce T cell exhaustion. IL1069,70 and transforming 
growth factor-β (TGF-β)71 are well described cytokines involve in T cell dysfunctions. Cells 
are also known to inhibit T cells functions and induce exhaustion72. Exhausted T cells lack 
effector functions like cytotoxicity, IFNγ, TNFα, proliferation capacity and have apoptotic 
features as compare to effector and memory T cells and fail to mount effective immune 
response52 (Fig. 1.12). 
 
1.1.3b B cells 
B cells or B lymphocytes are antibody (Ab) secreting cells of adaptive immune 
system. Antibodies also known as immunoglobulins (Ig) are part of humoral immunity and 
they act directly against extracellular pathogen or involve other immune components to 
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eliminate pathogen or pathogen bearing cells. B cells besides producing antibodies are also 
professional antigen presenting cells and secret cytokines. Development of B cells start in 
bone marrow includes several stages such as change in surface molecules expression, 
immunoglobulin gene rearrangement and selection process, that lead to production of 
immature B cells. After that immature B cells enter spleen and complete its development to 
become mature B cells2,3,73.  
There are three major populations of B cells depending mainly on their surface 
phenotype; functions and anatomical locations include B-2 B cells (Follicular B cells), B1 B 
cells and marginal zone B cells2,3 (Fig. 1.13).  B-2 B cells are mostly present in lymphoid 
follicles of SLOs. B-1 B cells are present in peritoneal and pleural cavities, and marginal zone 
B cells are present in marginal zone of spleen.	
	
1.1.3b1 B cell activation 
B cell activation starts when B-cell receptors (BCRs) bind to its specific antigen. There 
are two main ways for B cell activation that depends on nature of antigens2,3. One is T cell 
dependent (TD) and other is T cell independent (TI) B cell activation. Non-protein microbial 
antigens like lipids, nucleic acids and glycoproteins cannot stimulate classical T cell response 
but are able to stimulate Ab production in the absence of T cells and called as thymus or T 
cell independent (TI) antigens74. On the other hand, the antibody production to protein 
antigens requires T cell involvement, and these antigens are described as thymus 
dependent (TD) antigens75. TI responses are often of shorter duration than T cell 
dependent B cell responses. 
																																													Figure 1.13: B cell subsets 
                     Owen JA, et all. Kuby Immunology, 7th edition, 2013 
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TD B cell activation- After antigen exposure, antigen bind to its specific BCR on B 
cell and this lead to B cell activation (signal 1, Fig. 1.14). Activated B cell then 
internalize and process the antigen and present it to already primed CD4+ T cell with 
same antigen. This lead to further activation of CD4+ T cell and it express CD40L, which 
binds to CD40 on the B cell surface and induces signaling (signal 2, Fig. 1.14). At same 
time, activated CD4+ T cell release cytokines (Signal 3, Fig. 1.14) that leads to B cell 
proliferation. Some of the proliferating B cells differentiate into short-lived plasma cells and 
memory B cells outside the follicles (germinal center independent) form primary focus and 
produce Abs in initial stage of immune response which are mainly class IgM75,76.  
 
Activated B cells move to the follicle and undergo rapid proliferation and clonal 
expansion to form the germinal center, which is accompanied by somatic hypermutation 
(SHM), and affinity maturation through interaction with immune complex-coated follicular 
dendritic cells (FDCs) and antigen-specific T follicular helper cells (TFH cells). After that Ig 
MZ, B-1 cells 
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																																								Figure 1.14: B cell activation 
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class switching take place under the influence of cytokines produced by activated CD4+ T 
cell (Fig. 1.14). These germinal center B cells then exit the germinal center, either as 
memory B cells or as fully differentiated long-lived plasma cells which roam all over body 
and produce large amount of Abs and finally make home in bone marrow for life time75,76.  
TI B cell activation is depending on TI antigens, which are further divided in to two 
subclasses, TI type 1 (TI-1) and TI type 2 (TI-2) on the mechanism of B cell activation 
by them. TI-1 antigens are LPS, CpG or Ploy IC, act via TLRs and directly induce B cell 
division (Fig. 1.14) 74. At high concentrations, TI-1 antigens induce the proliferation and 
differentiation of most B cells regardless of antigen specificity (polyclonal activation). 
However, at low concentrations, they induce antigen-specific antibody responses. 
However, they are not able to undergo isotype switching or affinity maturation due to 
lack of T cell help. TI-2 antigens are polysaccharides that cross link the specific BCR and 
thus induce antigen specific B cell responses (Fig. 1.14)74. TI-2 antigens don’t have B 
cell activating activity and can activate only mature B cells to produce antibodies. After 
TI antigen challenge B cell get activated and differentiate in to plasma cells in extra 
follicular regions and produce low affinity mainly IgM Abs. TI antigens usually activate 
B-1 B and marginal zone B cells.  
1.1.3b2 Functions of B cells 
B cells are functional in two ways, one is antibody dependent and others are its 
cellular functions. Besides producing Abs, B cells are involved in antigen presentation and 
secrete different cytokines which lead to T cell stimulation or inhibition; help in memory 
formation, lymphoid tissue organogenesis, autoimmunity and tumor immunity77,78.  
Antibody secreted by B cells protects the host from pathogen by involving in different 
crucial functions. Abs can directly neutralize the pathogen by binding and blocking the 
receptors that pathogen use to get entry in to a cell. Abs can opsonize pathogen by binding to 
them and recruiting phagocytic cells, which engulf and digest Ab-Ag complex (Fig. 1.15). 
Abs bind directly to pathogen or antigen expressing infected cells that can initiate the 
complement cascade, which can kill pathogen and infected cells (Fig. 1.15). 79-81. Abs bind to 
antigen expressing infected cells and can recruit cytotoxic natural killer (NK) cells by making 
interaction with FcR on NK cells that lead NK cell activation and killing of infected cell in a 
process called antibody- dependent cell-mediated cytotoxicity (ADCC) (Fig. 1.15) 79-81. 
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1.2 Pathogens  
For this study, we used different pathogens include lymphocytic choriomeningitis 
virus (LCMV), recombinant-LCMV (r-LCMV), recombinant listeria monocytogenes and wild 
type listeria monocytogenes.  
1.2.1 Lymphocytic choriomeningitis virus (LCMV) 
LCMV was first discovered by Charles Armstrong in 1933 during epidemic 
encephalitis in St. Louis. The natural host of LCMV is mouse but also infect wide range of 
animals including human and responsible for aseptic meningitis and encephalitis82. LCMV 
belongs to arenaviridae family and is an enveloped virus consists of glycoprotein (GP) spikes 
on surface and two negative sense-single stranded RNA segments named L and S, which are 
wrapped along nucleoproteins83. LCMV infect cells by binding through their glycoprotein to 
cell surface receptor called alpha-dystroglycan (α-DG)84. Alpha-dystroglycan is a receptor for 
extracellular matrix and widely expressed on cells84. Upon receptor binding LCMV is 
internalized in to cell vesicle where viral membrane fuse to cell and release its genome in 
cytoplasm85.  
                                 Figure 1.15: Antibody functions 
                    Owen JA, et all. Kuby Immunology, 7th edition, 2013 
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LCMV is a non-cytopathic virus that replicates in host cells without harming them. The 
progress of LCMV infection in mice mainly depends upon dose and strain of LCMV used. 
There are four known strains of LCMV, two are neurotropic include Armstrong (mild) and 
clone13 (aggressive) and two are hepatotropic include WE (mild) and Docile (aggressive)86,87. 
Infection with mild strains of LCMV in mice induce acute infection and resolved with in 2 
weeks with the help of virus specific cytotoxic T lymphocyte (CTL). But aggressive LCMV 
strains lead to T-cell exhaustion and virus persistent88. Lower infection dose of LCMV induce 
strong CTL response and clear virus quickly with minimal pathology, however higher LCMV 
dose result in clonal T cell exhaustion, viral persistent and little immunopathology. But 
intermediate dose partially exhaust  T cells and result in massive immunopathology and high 
mortality89.  
Recombinant LCMV (rLCMV) express mutated form of LCMV-GP that can infect cells 
and viral genome can undergo transcription and replication but can’t form infectious 
particles90. rLCMV have antigenic properties and can induce CTL response90,91.  
1.2.2 Listeria Monocytogenes (LM) 
Listeria monocytogenes (LM) a gram-positive facultative intracellular bacterium92. 
Infection with LM generate CTL response which is important for elimination of LM from 
host93. Recombinant LM (LM-GP33) that express the GP(GP33-41) of LCMV and infection 
of mice with LM-GP33 result in GP33 specific CTL response94,95. LM-GP33 mostly used as a 
vaccine to generate LCMV specific T cell response94,95.  
1.3 Mouse models  
v P14 × CD45.1 
These transgenic mice have T-cell receptor (TCR) specific for the LCMV 
glycoprotein epitope 33 (GP-33-41)96. P14 mice are crossed with CD45.1 congenic 
mice to track lymphocytes during adoptive transfer experiments. 
v Usp18–/–  
These mice lack functional Ubiquitin-specific peptidase 18 (USP18 or UBP43) 
protein. USP18 act as a negative regulator of interferon signaling97. 
v Jh–/– 
These mice lack gene for heavy chain joining region and fail to develop functional B 
cells98. 
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v PD1–/– 
PD1–/– mice lack functional programmed cell death 1 protein, also known as Pdcd1. 
PD1 is a cell surface inhibitory molecules and negatively regulate functions of T 
cells99. 
 
v PDL1–/– 
These mice are deficient of PDL1, which is a ligand for PD1.  These mice exhibit 
higher functional activity of T cells100. 
v CD169-DTR 
These transgenic mice express human diphtheria toxin receptor (DTR) under the 
promoter of CD169 gene. In these mice, CD169+ macrophages can be depleted 
selectively by administration of diphtheria toxin101. 
v IFNAR–/– 
These mice lack the receptors for interferon a and b, IFN signaling, and are highly 
susceptible to viral infection102.  
v IFNβ mob/mob  
These are IFN-b reporter knock-in mice which express yellow fluorescent protein 
(YFP) under the IFN-b promoter. Activation of IFN-b promotor lead to YFP 
expression and visualization of IFN-b  producing cells103.    
v Prf1–/– 
These mice are perforin deficient, and CTL and NK cells from these mice lack cell 
mediated cytolysis effector functions104. 
v B2m –/– 
These mice are lacking β2-Microglobulin that is a part of MHC class I molecule, 
expressed on all nucleated cells and needed for development of CD8+ T-cell in thymus 
105. These mice are lacking CD8+ T cells.  
v KL25 × CD45.1 
In these transgenic mice, heavy chains of immunoglobulins are specific for LCMV. So 
these mice naturally have LCMV neutralizing antibodies in serum106. 
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CD169+ macrophages regulate PD-L1 expression via
type I interferon and thereby prevent severe
immunopathology after LCMV infection
Namir Shaabani*,1,2,3,8, Vikas Duhan1,8, Vishal Khairnar1,8, Asmae Gassa1, Rita Ferrer-Tur1, Dieter Häussinger2, Mike Recher4,
Gennadiy Zelinskyy5, Jia Liu6, Ulf Dittmer5, Mirko Trilling5, Stefanie Scheu7, Cornelia Hardt1, Philipp A Lang2,8, Nadine Honke1,2,8 and
Karl S Lang*,1,2,8
Upon infection with persistence-prone virus, type I interferon (IFN-I) mediates antiviral activity and also upregulates the expression
of programmed death ligand 1 (PD-L1), and this upregulation can lead to CD8+ T-cell exhaustion. How these very diverse functions
are regulated remains unknown. This study, using the lymphocytic choriomeningitis virus, showed that a subset of CD169+
macrophages in murine spleen and lymph nodes produced high amounts of IFN-I upon infection. Absence of CD169+
macrophages led to insufficient production of IFN-I, lower antiviral activity and persistence of virus. Lack of CD169+ macrophages
also limited the IFN-I-dependent expression of PD-L1. Enhanced viral replication in the absence of PD-L1 led to persistence of virus
and prevented CD8+ T-cell exhaustion. As a consequence, mice exhibited severe immunopathology and died quickly after infection.
Therefore, CD169+ macrophages are important contributors to the IFN-I response and thereby influence antiviral activity, CD8+
T-cell exhaustion and immunopathology.
Cell Death and Disease (2016) 7, e2446; doi:10.1038/cddis.2016.350; published online 3 November 2016
Chronic viral infection is a serious health concern. Many
viruses, such as human immunodeficiency virus (HIV),
hepatitis B virus (HBV) and hepatitis C virus (HCV), lead to
viral persistence and dysfunction of adaptive immunity.1 The
persistence of HCV can lead to chronic liver inflammation,
resulting in liver cirrhosis, liver steatosis, end-stage liver failure
or hepatocellular carcinoma. Many of these clinical problems
are related to the constant activity of cytotoxic CD8+ T cells.
Therefore, exhaustion of CD8+ T cells may be essential for
preventing severe immunopathology in chronic infections.
Although mechanisms of exhaustion that involve inhibitory
receptors have been thoroughly studied on the T-cell side, it
has not yet been determined which cell types modulate the
expression of the ligands for inhibitory receptors and thereby
contribute to T-cell exhaustion during chronic viral infection.
Identifying such mechanisms may help explain why some
patients suffer from severe immunopathology during chronic
infection, whereas others do not.
Type I interferon (IFN-I) plays a dual role during viral
infection. On the one hand, it limits viral replication because it
directly induces antiviral factors in the infected cell.2,3
Consequently, the absence of the interferon-α/β receptor
(IFNAR) promotes viral replication and can result in
persistence of virus.4–6 On the other hand, sustained IFN-I
signaling induces immunosuppressivemechanisms, including
the production of interleukin-10 (IL-10) and the expression of
programmed cell death ligand 1 (PD-L1).7–9 IL-10 and
PD-L1 are important inhibitors of CD8+ T cells and thereby
limit the function of virus-specific CD8+ T cells. Programmed
cell death protein 1 (PD-1) is upregulated on all activated
CD8+ T cells,10 a finding suggesting that the regulation of its
ligand (PD-L1) determines the fate of virus-specific
CD8+ T cells. Viral infection can upregulate PD-L1 expression
by target cells, and this expression mediates the immune
escape of these cells from killing by cytotoxic T lymphocytes
(CTLs).11 How professional immune cells regulate
PD-L1 expression during an ongoing infection is not well
defined.
Here we report that during infection with lymphocytic
choriomeningitis virus (LCMV), CD169+ macrophages
prolong the IFN-I response that mediates antiviral activity. In
addition, a prolonged IFN-I response induces PD-L1
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2.1 Abstract 
	
Upon infection with persistence-prone virus, type I interferon (IFN-I) mediates antiviral 
activity and also upregulates the expression of programmed death ligand 1 (PD-L1), and this 
upregulation can lead to CD8+ T-cell exhaustion. How these very diverse functions are 
regulated remains unknown. This study, using the lymphocytic choriomeningitis virus, 
showed that a subset of CD169+ macrophages in murine spleen and lymph nodes produced 
high amounts of IFN-I upon infection. Absence of CD169+ macrophages led to insufficient 
production of IFN-I, lower antiviral activity and persistence of virus. Lack of 
CD169+ macrophages also limited the IFN-I-dependent expression of PD-L1. Enhanced viral 
replication in the absence of PD-L1 led to persistence of virus and prevented CD8+ T-cell 
exhaustion. As a consequence, mice exhibited severe immunopathology and died quickly 
after infection. Therefore, CD169+ macrophages are important contributors to the IFN-I 
response and thereby influence antiviral activity, CD8+ T-cell exhaustion and 
immunopathology. 
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2.2 Introduction 
Chronic viral infection is a serious health concern. Many viruses, such as human 
immunodeficiency virus (HIV), hepatitis B virus (HBV) and hepatitis C virus (HCV), lead to 
viral persistence and dysfunction of adaptive immunity107. The persistence of HCV can lead 
to chronic liver inflammation, resulting in liver cirrhosis, liver steatosis, end-stage liver failure 
or hepatocellular carcinoma. Many of these clinical problems are related to the constant 
activity of cytotoxic CD8+ T cells. Therefore, exhaustion of CD8+ T cells may be essential 
for preventing severe immunopathology in chronic infections. Although mechanisms of 
exhaustion that involve inhibitory receptors have been thoroughly studied on the T-cell side, 
it has not yet been determined which cell types modulate the expression of the ligands for 
inhibitory receptors and thereby contribute to T-cell exhaustion during chronic viral 
infection. Identifying such mechanisms may help explain why some patients suffer from 
severe immunopathology during chronic infection, whereas others do not. 
 
Type I interferon (IFN-I) plays a dual role during viral infection. On the one hand, it 
limits viral replication because it directly induces antiviral factors in the infected cell 108,109. 
Consequently, the absence of the interferon-α/β receptor (IFNAR) promotes viral replication 
and can result in persistence of virus 102,110,111. On the other hand, sustained IFN-I signaling 
induces immunosuppressive mechanisms, including the production of interleukin-10 (IL-10) 
and the expression of programmed cell death ligand 1 (PD-L1) 68,112,113. IL-10 and PD-L1 are 
important inhibitors of CD8+ T cells and thereby limit the function of virus-specific CD8+ T 
cells. Programmed cell death protein 1 (PD-1) is upregulated on all activated CD8+ T cells 114, 
a finding suggesting that the regulation of its ligand (PD-L1) determines the fate of virus-
specific CD8+ T cells. Viral infection can upregulate PD-L1 expression by target cells, and 
this expression mediates the immune escape of these cells from killing by cytotoxic T 
lymphocytes (CTLs) 115. How professional immune cells regulate PD-L1 expression during an 
ongoing infection is not well defined. 
Here we report that during infection with lymphocytic choriomeningitis virus (LCMV), 
CD169+ macrophages prolong the IFN-I response that mediates antiviral activity. In addition, 
a prolonged IFN-I response induces PD-L1 expression in the liver. The absence of 
CD169+ macrophages reduces antiviral IFN-I activity and also limits PD-L1 expression. As a 
result, mice exhibit overwhelming viral replication in the absence of CD8+ T-cell exhaustion, 
and this replication results in severe immunopathology and death of mice. 
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2.3 Results 
2.3.1 Depletion of CD169+ macrophages affects a subtype of F4/80+ macrophages 
in the liver and viral control 
In order to study the role CD169+ cells, we used CD169 diphtheria toxin receptor 
(CD169-DTR) mice that express DTR under the CD169 promoter. Treating these mice with 
diphtheria toxin (DT) specifically depletes CD169+ cells. Interestingly, we found that after 
DT treatment, not only CD169+ cells in lymphoid organs were depleted but also the 
CD169+ cell number in the liver was reduced (Figure 1a and Supplementary Figure S1). 
Next we wondered on which cell type CD169 is expressed and whether its expression is 
upregulated during viral infection. To study this, we infected C57BL/6 wild type (WT) mice 
with LCMV strain WE and analyzed the expression of CD169 on different cell types in 
comparison with non-infected mice. We found that, without infection, CD169 is expressed on 
different cell types in the bone marrow and on F4/80+ cells in the liver and spleen 
(Supplementary Figure S2). After infection, CD169 was mostly upregulated in the bone 
marrow, on different cell populations in the spleen and on F4/80+ and Ly6C+ cells in the liver, 
whereas we did not detect an upregulation of CD169 in the lymph nodes (LNs) 
(Supplementary Figure S2 and Figure 1b). By analyzing the number of F4/80+ cells, we 
found a reduction in F4/80+ macrophages in the liver even in non-infected mice (Figure 1c). 
This means that a subtype of F4/80+ macrophages express CD169 in the liver under naive 
conditions. This raised the question whether depletion of CD169+ cells has an impact on 
phagocytic activity. We infected WT and CD169-DTR mice with LCMV-WE and measured 
viral titer in the blood. We detected more viruses in the blood of CD169-DTR mice after 
10 min of infection in CD169-DTR mice (Figure 1d). However, virus was cleared from blood 
in both groups within 60 min post infection (Figure 1d). In a previous study, we showed that 
infecting WT mice with low dose of LCMV-WE ( 200 PFU) leads to viral replication only 
in the spleen but not in the liver. The inhibition of viral replication in the liver was IFN-I 
dependent because lack of interferon type I receptor led to high viral titer in the liver 116. Here 
we found that depletion of CD169+ macrophages in CD169-DTR mice did not affect viral 
replication in the spleen and LNs (Figure 1e). Also, after 5 days we could not detect 
enhanced viral replication (Figure 1e). However, CD169+macrophages were essential for 
controlling LCMV replication in the liver 5 days after infection (Figure 1e). Histological 
staining showed that the presence of CD169+macrophages in WT mice could prevent 
infection of hepatocytes, whereas mice without CD169+ macrophages exhibited virus-infected 
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hepatocytes (Figure 1f). We conclude that depletion of CD169+ macrophages affects a 
subtype of F4/80+macrophages in the liver which leads to enhanced viral replication. 
 
2.3.2  CD169+ macrophages in the spleen and lymph nodes contribute to the 
production of IFN-I 
In a previous study, we found that after viral infection with the cytopathic vesicular 
stomatitis virus (VSV), macrophages in liver are contributing mainly in taking up the virus. 
Even though viral replication is suppressed in the liver and allowed in CD169+ macrophages 
in the spleen and LNs in an IFN-I dependent manner 117. To define the role of 
CD169+ macrophages during infection with the non-cytopathic LCMV, we first infected 
C57BL/6 wild-type (WT) mice with 2 × 106 plaque-forming units (PFU) of LCMV strain WE 
and analyzed the viral uptake. After 1 h, viral RNA levels in various organs were analyzed. 
We found that the liver initially takes up most of the virus followed by the spleen (Figure 2a). 
However, one day after infection, viral replication was suppressed in the liver and allowed in 
the spleen and LNs (Figure 2b). This suppression was IFN-I dependent because infecting 
IFN-I receptor-deficient mice (Ifnar–/–) led to an increase in viral titer in the liver (Figure 2b). 
Histological staining of spleen and LNs showed that viral replication in spleen and LNs was 
mostly occurring in the CD169+ macrophages and that LCMV nucleoprotein (LCMV-NP) 
partially co-localized with CD169+ macrophages (Figure 2c). Because virus can induce IFN-I 
via activation of pattern recognition receptors 118, we hypothesized that replication of virus in 
CD169+ macrophages may lead to induction of IFN-I in these cells. To test this hypothesis, 
we infected IFN-β reporter knock-in mice (IFNβmob/mob mice) with LCMV. In these mice the 
yellow fluorescent protein (YFP) is expressed after activation of the ifnb promoter. 
Additionally, we infected C57BL/6 mice as negative controls. Two days after LCMV 
infection, we analyzed the expression of YFP. Infection of IFNβmob/mob mice led to the 
expression of YFP in 0.008% of all splenocytes (Figure 2d), a finding suggesting that these 
were the main IFN-I producers during LCMV infection 42,103.  WT mice did not exhibit YFP 
expression after LCMV infection (Figure 2d). Gating of IFN-I-producing cells showed that 
approximately 10% of IFN-I producers expressed CD169. Next, we performed real-time 
polymerase chain reaction (RT-PCR) for the early IFN-I genes Ifn-α4 and Ifn-β1 in spleen 
and LNs to determine whether the depletion of CD169+ macrophages can influence IFN-I 
production. We found that LCMV infection induced strong expression of Ifn-α4 and Ifn-
β1 mRNA in the spleen and LNs of WT mice (Figure 2e). DT-treated CD169-DTR mice 
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exhibited significantly lower mRNA levels of Ifn-α4 and Ifn-β1 than WT mice, especially on 
day 5 after infection (Figure 2e). In line with these results, we found that systemic IFN-
α levels were significantly lower in the serum of DT-treated CD169-depleted mice than in 
WT mice 2 days after infection (Figure 2f). In conclusion, we found that early replication of 
LCMV in CD169+ macrophages resulted in IFN-I production. Especially at later stages of 
infection, CD169+ macrophages were responsible for most of the systemic production of IFN-
α. 
2.3.3 CD169+ macrophages have limited impact on CD8+ T cell priming but are 
essential for controlling acute viral infection and prevention of immunopathology 
To determine whether early priming of CD8+ T cells is influenced by CD169+ 
macrophages, we transferred carboxyfluorescein succinimidyl ester (CFSE)-labeled 
splenocytes from naive CD45.1 x LCMV-P14 T-cell receptor transgenic mice (CD45.1 x P14 
mice) into WT or CD169-DTR mice. P14 mice express a LCMV–GP33-41–specific TCR as a 
transgene 96. Infection with LCMV resulted in proliferation of virus-specific CD8+ T cells in 
the spleen and LNs in both WT and CD169-DTR mice (Figure 3a). The total number of 
virus-specific CD8+ T cells was slightly higher in the absence of CD169+ macrophages 
(Figure 3b). This finding suggests that CD169+ macrophages exert limited impact on 
CD8+ T-cell priming. 
Next we investigated the activation markers of GP33-specific tetramer positive CD8+ T 
cells (Tet-GP33+). We treated WT and CD169-DTR mice with DT and infected them with 
LCMV-WE. We found, after 8 days of viral infection, that in CD169-DTR mice, Tet-
GP33+ CD8+ T cells are more highly activated than in WT mice, as determined with 
granzyme B (GzmB), CD43, PD-1 and Lag3 (Figure 3c). Together, our findings suggest that 
the absence of CD169+ macrophages does not affect priming of virus-specific CD8+ T cells. 
The absence of CD169+ macrophages was associated with a weak IFN-I response but 
normal CD8+ T-cell priming. We next investigated the impact of CD169+macrophages on 
overall virus control and pathology after infection with an acute virus strain. We found that 
LCMV persists in LNs, spleen and liver of CD169-DTR mice but is controlled by WT mice 
(Figure 3d). This finding was in line with enhanced liver cell damage, because alanine 
aminotransferase (ALT) activity was dramatically increased in CD169-depleted mice (Figure 
3e) and these mice became terminally ill after acute infection, whereas WT mice survived 
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(Figure 3f). We conclude that absence of CD169+ cells has limited impact on T-cell priming 
but it leads to viral persistence and immunopathology. 
 
2.3.4 CD169+ macrophages induce PD-L1 expression which prevents 
immunopathology 
                      
IFN-I plays two main roles during LCMV infection. First, it directly inhibits viral 
replication by inducing antiviral enzymes. Second, it upregulates PD-L1 expression, and this 
upregulation can lead to exhaustion of CD8+ T cells. This finding suggested that the absence 
of CD169+ macrophages not only limits direct antiviral effects but may also influence 
CD8+ T-cell functions. The fact that the liver strongly responds to antiviral IFN-I, we 
investigated whether PD-L1 expression is regulated by IFN-I in the liver. We infected WT 
and Ifnar–/– mice with LCMV and analyzed the expression of PD-L1 in the liver. We found 
that during LCMV infection, Kupffer cells express high levels of PD-L1 (Figure 4a). The 
absence of IFN-I signaling in Ifnar–/–mice inhibits the upregulation of PD-L1 on Kupffer cells 
during acute infection (Figure 4a). Next we investigated whether CD169+ macrophages affect 
PD-L1 expression. To do so we stained the cells for PD-L1 in CD169-depleted mice after 
LCMV infection. PD-L1 expression was strongly reduced in the liver of DT-treated CD169-
DTR mice (Figure 4b). This finding suggests that CD169+ macrophages-derived IFN-I is 
essential for PD-L1 upregulation in the liver. 
We speculate that higher viral replication and a reduction of CD8+ T-cell exhaustion due 
to lack of PD-L1 expression in CD169-DTR mice are responsible for the death of the mice. 
Indeed depletion of CD8+ T cells prevented death in 70% of the CD169-DTR mice (Figure 
4c). In order to compensate for PD-L1 expression in CD169-DTR mice, we generated bone 
marrow-derived macrophages (BMDMs) from WT and PD-L1-deficient mice and treated 
them with IFN-I in order to increase PD-L1 expression (Figure 4d). Afterwards, we 
transferred the BMDMs into two groups of LCMV-infected CD169-DTR mice. The group 
that received WT cells survived after infection with LCMV, whereas the group that received 
PD-L1–deficient cells died of infection (Figure 4e). In conclusion, the absence of 
CD169+ macrophages leads to a lethal immunopathology because of the limited expression of 
PD-L1. 
 
	     31 
						
2.3.5  CD169+ macrophages prevent severe immunopathology during chronic 
viral infection 
We found that during acute LCMV infection, the absence of CD169+ macrophages results 
in insufficient control of virus and limited CD8+ T-cell exhaustion. Both effects result in 
severe immunopathology. Next we analyzed how CD8+ T-cell responses develop during 
overwhelming viral replication. To do so, we used the LCMV strain Docile, which is known 
to persist and is associated with severe CD8+ T cell exhaustion in WT mice 119. In WT mice 
and CD169-DTR mice infected with LCMV-Docile, virus persisted after infection (Figure 
5a). CD169-DTR mice generated more virus-specific CD8+ T cells in the spleen than did WT 
mice, whereas in both types of mice the numbers of these cells in the liver were comparable 
(Figure 5b). Moreover, CD8+ T cells in CD169-DTR mice exhibited higher frequencies of 
IFN-γ producing CD8+ T cells in the liver (Figure 5c). In the absence of 
CD169+macrophages, liver cell damage was exacerbated (Figure 5d) and mice became 
terminally ill after infection (Figure 5e). To check whether this severe liver cell damage and 
clinical disease was dependent on CD8+ T-cell-mediated immunopathology, we depleted 
CD8+ T cells in both groups. We found that absence of CD8+ T cells in CD169-DTR mice 
prevented morbidity and mortality (Figures 5d and e). To determine whether the 
immunopathology in CD169-DTR mice was due to their inability to induce PD-L1 
expression, we infected PD-1-deficient mice with LCMV-Docile. Indeed, the absence of PD-1 
during chronic LCMV infection led to liver damage, as determined by serum ALT activity 
(Figure 5f); this phenotype resembled that of mice deficient in CD169+ cells (Figure 5d). 
The immunopathology also led to the death of LCMV-Docile-infected PD-1-deficient mice 
(Figure 5g). From these findings we concluded that CD169+ macrophages are essential for 
preventing severe immunopathology and death during chronic viral infection. 
2.4 Discussion 
The results of this study show that CD169+ macrophages are important contributors to 
prolonged IFN-I production after LCMV infection. This prolonged production is associated 
with reduced viral replication in peripheral organs and with upregulation of PD-L1. Depletion 
of CD169+ macrophages results in enhanced viral propagation and prevents CD8+ T-cell 
exhaustion, both of which contribute to severe immunopathology. 
The function of CD8+ T cells must be carefully regulated to ensure the elimination of 
virus without the development of severe immunopathology. IFN-I has been found to be a 
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crucial innate cytokine that strongly regulates CD8+ T cell function. First, it protects CD8+ T 
cells from cytotoxicity induced by natural killer cells 120. Second, IFN-I upregulates IL-10 and 
PD-L1, and this upregulation contributes to the exhaustion of CD8+ T cells 112,113. Genetic 
deletion of IL-10 or partial blockade of PD-1 enhances the control of virus during chronic 
infection 68,70. Earlier studies showed that PD-1high CTLs are effective and important in 
reducing viral titers during acute infection 114. The factor that determines whether PD-1 
expression can contribute to CD8+ T cell exhaustion is the upregulation of PD-L1 on cells that 
contact CD8+ T cells 115. In addition to PD-1, 13 other inhibitory cell surface pathways have 
been shown to be overexpressed in exhausted CD8+ T cells 121. In addition to passive defects 
in metabolism, active suppression is needed for functional exhaustion of CD8+ T cells 121. The 
results of the present study show that mice lacking CD169+ macrophages cannot control 
LCMV because of the absence of prolonged production of IFN-I. Therefore, CD169+ 
macrophages may be the crucial cell type that balances viral suppression and CD8+ T cell 
exhaustion. 
In earlier studies using VSV, we found that CD169+ macrophages are essential for 
enforcing viral replication in the spleen and thereby play an important part in immune 
activation 116,117,122. In this study using LCMV, we did not find reduced priming of adaptive 
immune cells; however, we did find reduced induction of IFN-I. There may be two reasons 
for these diverse functions of CD169+ macrophages in VSV infection and LCMV infection. 
First, LCMV can replicate not only in follicular dendritic cells but also in CD169+ 
macrophages and conventional dendritic cells 116. Therefore, enforced viral replication does 
not depend entirely on CD169+ macrophages that will lead to early CD8+ T cell activation and 
IFN-I production. Second, CD169+ macrophages in the liver may also participate in antiviral 
effector functions. Therefore, the absence of CD169+ macrophages may also limit local IFN-I 
production in the liver.   
It remains to be answered how these findings can be transferred to chronic viral 
diseases in humans. The role of various subtypes of Kupffer cells during chronic viral 
infection has not been well studied. Some human macrophages express CD169 123. Whether 
these macrophage populations similarly contribute to the prolonged induction of IFN-I during 
chronic viral infections in humans remains to be studied.  
In conclusion, we found that CD169+ macrophages contribute to viral propagation and 
CD8+ T-cell exhaustion during viral infection. CD169+ macrophage-derived IFN-I is essential 
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for preventing viral replication in peripheral organs and for inducing PD-L1 expression so 
that severe immunopathology can be prevented. 
2.5 Methods 
2.5.1 Mice 
All mice were sex, age and weight matched to their controls. CD169-DTR mice were 
generated in the Tanaka lab 101, and IFNβmob/mob mice were generated in the Scheu lab 103. P14 
mice expressing a LCMV–Gp33-41–specific TCR as a transgene were used for adoptive 
transfer experiments 96. All of these mice were maintained on a C57BL/6 background, as were 
PD-1–/–, PD-L1–/–, and Ifnar–/– mice. All experiments were performed with the animals housed 
in single ventilated cages and with the authorization of the Veterinäramt Nordrhein Westfalen 
(Düsseldorf, Germany) in accordance with the German law for animal protection or the 
institutional guidelines of the Ontario Cancer Institute. 
 
2.5.2 Depletion of the cells  
 For CD8+ T-cell depletion, 500 µg of anti-CD8 antibody clone YTS 169.4 (Bioxcell, 
West Lebanon, NH, USA) was injected intraperitoneally on days 1, 3 and 5. For the depletion 
of CD169+ macrophages, 30 µg/kg body weight DT (Sigma Aldrich, St. Louis, MO, USA) 
was injected intraperitoneally on days −3, 2 and 5. 
 
2.5.3 Generation of bone marrow–derived macrophages and transfer 
experiment  
 Primary macrophages were generated by isolating bone marrow from femurs and 
tibias of mice and eliminating erythrocytes. Macrophages were generated by culturing bone 
marrow cells in very low endotoxin Dulbecco’s modified Eagle’s medium (VLE-DMEM) 
(Biochrom, Berlin, Germany) supplemented with 10% (v/v) fetal bovine serum (Biochrom), 
0.1% (v/v) β-mercaptoethanol (β-ME) (Invitrogen, Carlsbad, CA, USA) and 10 ng/ml 
macrophage colony-stimulating factor (made in house). Cells were treated with 100 units of 
IFN-α4 (PBL Assay Science, Pistcataway, NJ, USA) on day 7 for 12 h. On day 8 of 
harvesting, cells were washed and 8 × 106 cells were transferred into LCMV-infected mice. 
Cells transfer was performed twice on day 5 and day 7 of infection. 
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2.5.4 Plaque assay 
 Virus titers were measured with a focus-forming assay as previously described 124. 
2.5.5 Real-time polymerase chain reaction 
Total RNA was extracted with Trizol (Life Technologies, Carlsbad, CA, USA). The RNA 
was reverse-transcribed into cDNA with the Quantitect Reverse Transcription Kit (Qiagen, 
Hilden, Germany). Gene expression analysis was performed with assays from Qiagen: 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH; QT01658692), IFN-α (QT01774353) 
or IFN-β (QT00249662). Relative quantities (RQs) were determined with the equation RQ=2–
ddCt. 
2.5.6 Lymphocyte transfer 
Splenocytes from P14/CD45.1 mice were labeled with 1 µM CFSE (Invitrogen) and 
injected intravenously into mice. One day later, mice were infected with LCMV-WE. The 
proliferation of P14 T cells was assessed in the spleen and LNs with CFSE dilution by flow 
cytometry. 
2.5.7 Flow cytometry 
Tetramers were provided by the National Institutes of Health (NIH) Tetramer Facility 
(Emory University, Atlanta, GA, USA). Cells were stained with allophycocyanin (APC)-
labeled GP-33 major histocompatibility complex class I tetramers (GP-33/H-2Db) for 15 min 
at 37 °C. After incubation, the samples were stained with anti-CD8 (BD Biosciences, San 
Diego, NJ, USA) for 30 min at 4 °C. Erythrocytes were then lysed with 1 ml BD lysing 
solution (BD Biosciences), washed once and analyzed by flow cytometry. Absolute numbers 
of GP-33-specific CD8+ T cells per microliter of blood were determined by fluorescence-
activated cell sorting (FACS) analysis using fluorescent beads (BD Biosciences). IFN-γ was 
purchased from eBiosciences (San Diego, CA, USA). 
2.5.8 Enzyme-linked immunofluorescent assays 
ELISAs for IFN-α were performed according to the manufacturer’s protocol (PBL Assay 
Science). 
2.5.9 Histology 
Histologic analyses used snap-frozen tissue. Sections were stained with anti-PD-L1 
(eBioscience, CA, USA), anti-CD169 (AbD Serotec, Oxfordshire, UK), anti-CD45R (B220) 
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(eBioscience, CA, USA), anti-F4/80 (eBioscience, CA, USA) or anti-LCMV-NP (made in-
house). 
2.5.10 Alanine aminotransferase 
Biochemical analyses were performed by the Central Laboratory, University hospital, 
Essen, Germany. 
 
2.5.11 Statistical analysis 
Unless otherwise stated, data are expressed as mean±S.E.M. Student’s t-test was used to 
detect statistically significant differences between groups. Significant differences between 
several groups were detected by two-way analysis of variance (ANOVA). The level of 
statistical significance was set at P<0.05, P<0.01 or P<0.001. 
 
 2.6 Ethics Statement 
All experiments were performed with the animals housed in single ventilated cages. 
Experiments were conducted under the authorization of the Veterinäramt Nordrhein 
Westfalen (Düsseldorf, Germany) and in accordance with the German law for animal 
protection or the institutional guidelines of the Ontario Cancer Institute. The Landesamt für 
Natur, Umwelt und Verbraucherschutz Nordrhein-Westfalen (LANUV; State Agency for 
Nature, Environment, and Consumer Protection) approved all experiments (project numbers 
84-02.04.2014.A242 and 84-02.04.2012.A094). 
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2.8 Figure Legends 
2.8.1 Figure 1: Depletion of CD169+ macrophages affects a subtype of F4/80+ 
macrophages in the liver and viral control  
(a) Wild type (WT) and CD169 diphtheria toxin receptor (−DTR) mice were treated with 
diphtheria toxin (DT) day −3. On day 0, CD169+ cells were analyzed in the indicated organs 
(n=3). (b) Wild-type (WT) mice were infected with 30 plaque-forming units (PFU) of 
lymphocytic choriomeningitis virus strain WE (LCMV-WE) or left uninfected. On day 5, 
mean fluorescence intensity (MFI) of CD169 was measured in different organs (n=3). (c) 
Wild type (WT) and CD169 diphtheria toxin receptor (−DTR) mice were treated with 
diphtheria toxin (DT) day −3. On day 0 mice were infected with 30 PFU of LCMV-WE or left 
uninfected. On day 5, indicated organs were analyzed for F4/80+ cells (n=6 naive mice; n=3 
LCMV-infected mice). (d) WT and CD169 diphtheria toxin receptor (−DTR) mice were 
treated with DT and infected intravenously with 2 × 106 PFU LCMV-WE. Viral titers were 
measured in blood at indicated time points (n=6). (e) WT and CD169 diphtheria toxin 
receptor (−DTR) mice were treated with diphtheria toxin and infected intravenously with 30 
PFU LCMV-WE. Viral titers were measured in various organs at indicated time points (n=3). 
(f) Wild type and CD169-DTR mice were treated with diphtheria toxin and infected 
intravenously with 30 PFU LCMV-WE. Liver sections collected 5 days after infection were 
stained for F4/80 (green) and LCMV nucleoprotein (−NP) (red) (n=3). Scale bars, 100 µm 
(main images) or 50 µm (insets). NS, not significant, *P<0.05, **P<0.01, ***P<0.001. 
Statistical significance was detected by Student’s t-test (a and c) or analysis of variance 
(ANOVA) (e). 
 
2.8.2 Figure 2: CD169+ macrophages in the spleen and lymph nodes contribute 
to the production of IFN-I 
(a) Wild-type (WT) mice were infected intravenously with 2 × 106 PFU (plaque-forming 
units) lymphocytic choriomeningitis virus strain WE (LCMV-WE). Viral RNA expression in 
different organs was analyzed after 60 min with quantitative real-time polymerase chain 
reaction (qRT-PCR) (n=6). (b) WT and interferon-α/β receptor–null (Ifnar–/–) mice were 
infected intravenously with 2 × 104PFU LCMV-WE. One day after infection, viral titers in 
various organs were measured (n=4). (c) WT mice were infected intravenously with 2 × 
106 PFU of LCMV-WE. Spleen sections collected 1 day after infection or lymph node (LN) 
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sections collected 3 days after infection were stained for CD169 (red), LCMV nucleoprotein 
(NP) (green) and B220 (blue) (n=3). (d) WT and interferon-β (IFNβ) reporter knock-in 
(IFNβmob/mob) mice were infected intravenously with LCMV-WE (30 PFU) for 48 h. IFN-
β expression was analyzed by fluorescence-activated cell sorting (FACS) (n=3). (e and f) WT 
and CD169-DTR mice were treated with diphtheria toxin and infected intravenously with 
LCMV-WE (30 PFU). (e) IFN-α4 and IFN-β1 expression were measured with quantitative 
real-time polymerase chain reaction (qRT-PCR) at the indicated time points in spleen and 
LNs (n=3–4). (f) Levels of IFN-α in the serum were measured by enzyme-linked 
immunosorbent assay (ELISA) at the indicated time points (n=3–10). Scale bars, 
100 µm. *P<0.05, **P<0.01, ***P<0.001. Statistical significance was detected by Student’s t-
test (e) or analysis of variance (ANOVA) (f). 
 
2.8.3 CD169+ macrophages have limited impact on CD8+ T cell priming but are 
essential for controlling acute viral infection and prevention immunopathology 
(a and b) Splenocytes (107) from P14/CD45.1 mice were labeled with carboxyfluorescein 
succinimidyl ester (CFSE) and transferred to WT or CD169-DTR mice. On the next day, mice 
were infected with 30 PFU LCMV-WE. Four days after infection, (a) proliferation of 
CD45.1+CD8+ T cells was assessed by CFSE dilution in spleen and lymph nodes (LNs) (n=5). 
(b) Total number of CD45.1+CD8+T cells in the spleen and blood 4 days after infection (n=5). 
(c) WT and CD169-DTR mice were treated with DT and infected intravenously with 30 PFU 
LCMV-WE. Indicated markers were measured in GP33-specific tetramer positive CD8+ T 
cells in LNs, liver and spleen 8 days after infection (n=3). (d–f) WT and CD169 diphtheria 
toxin receptor (−DTR) mice were infected intravenously with 30 PFU LCMV-WE. (d) Viral 
titers were measured in LNs, spleen and liver at indicated time points (n=3). (e) Alanine 
aminotransferase (ALT) activity in the serum was measured 8 days after infection (n=3). (f) 
Survival of WT and CD169-DTR mice was monitored (n=15). NS, not 
significant, ***P<0.001. Statistical significance was detected by Student’s t-test (b and e), 
analysis of variance (ANOVA) (d) or log-rank (Mantel-Cox) test (f). 
 
2.8.4 Figure 4 CD169+ macrophages induce PD-L1 expression which inhibits 
immunopathology 
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(a) Wild type (WT) and interferon-α/β receptor-null (Ifnar–/–) mice were infected 
intravenously with 30 PFU of lymphocytic choriomeningitis virus strain WE (LCMV-WE). 
Three days after infection, liver sections were stained for F4/80 (green) and PD-L1 (red) 
(n=3). Scale bar, 100 µm. (b) WT and CD169 diphtheria toxin receptor (−DTR) mice were 
treated with diphtheria toxin and infected intravenously with 30 PFU LCMV-WE. Five days 
after infection, liver sections were stained for F4/80 (green) and PD-L1 (red) (n=3). Scale bar, 
100 µm. (c) Wild type (WT) and CD169 diphtheria toxin receptor (−DTR) mice were treated 
with DT and anti-CD8 antibody on days −1 and 3. Mice were infected intravenously with 30 
PFU LCMV-WE and survival of WT and CD169-DTR mice was monitored (n=6). (d) Bone 
marrow-derived macrophages (BMDM) from wild type (WT; red line) or programmed cell 
death ligand 1-null mice (PD-L1–/–; dashed line) were treated overnight with 100 units of IFN-
α4. Untreated WT macrophages were used as a control (filled line). Upregulation of PD-L1 
was measured by fluorescence-activated cell sorting (FACS). (e) CD169-DTR mice were 
infected with 30 PFU LCMV-WE. 8 × 106 BMDMs generated either from WT or from 
programmed cell death ligand 1-null mice (PD-L1–/–) were transferred into mice on days 5 
and 7 post infection. Survival of mice was monitored (n=6). NS, not significant, *P<0.05. 
Statistical significance was detected by log-rank (Mantel-Cox) test (c and e). 
	
2.8.5 Figure 5: CD169+ macrophages prevent severe immunopathology during 
chronic viral infection 
(a–c) Wild type (WT) and CD169 diphtheria toxin receptor (−DTR) mice were infected 
intravenously with 2 × 104 plaque-forming units (PFU) of lymphocytic choriomeningitis virus 
strain Docile (LCMV-Docile) for 11 days. (a) Viral titers were measured in various organs 
(n=6). (b) Number of virus-specific Tet-GP33+ CD8+ T cells was determined in the spleen 
and liver (n=7–8). (c) IFN-γ+CD8+ T cells were counted in the spleen and liver (n=7–8). (d) 
WT and CD169-DTR mice were infected intravenously with 2 × 104 PFU LCMV-Docile and 
treated with anti-CD8 depletion antibody or left untreated. Serum alanine aminotransferase 
(ALT) activity was measured after 13 days (n=3-4). (e) WT and CD169-DTR mice were 
infected intravenously with 2 × 104PFU LCMV-Docile and treated with anti-CD8 depletion 
antibody or left untreated. Survival of mice was monitored (n=8–33). (f and g) WT and 
programmed cell death protein 1-null (PD-1–/–) mice were infected intravenously with 2 × 
104 PFU LCMV-Docile. (f) Serum ALT activity was measured after 13 days (n=3). (g) 
Survival of mice was monitored (n=3). NS, not significant, *P<0.05, ***P<0.001. Statistical 
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significance was detected by Student’s t-test (b, c, d and f) or log-rank (Mantel-Cox) test 
(e and g). 
2.9 Supplementary Figures 
2.9.1 Figure 1: Gating strategy of CD169+ macrophages 
Wild-type (WT) and CD169 diphtheria toxin receptor (-DTR) mice were treated with 
diphtheria toxin (DT) day -3. On day 0, CD169+ cells were analyzed in the indicated organs 
(n = 3). 
2.9.2 Figure 2: Expression of CD169 on immune cells 
Wild-type (WT) mice were infected with 30 plaque-forming units (PFU) of lymphocytic 
choriomeningitis virus strain WE (LCMV-WE) or left uninfected. On day 5, the expression of 
CD169 was measured in different organs (dashed line: isotype control; black line: naive mice; 
red line: LCMV-infected mice) (n = 3). 
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Figure 1 
 
Figure 2.1: Depletion of CD169+ macrophages affects a subtype of F4/80+ macrophages 
in the liver and viral control. 
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Figure 2 
 
Figure 2.2: CD169+ macrophages in the spleen and lymph nodes contribute to the 
production of IFN-I.	
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Figure 3 
 
 
Figure 2.3: CD169+ macrophages have limited impact on CD8+ T cell priming but are 
essential for controlling acute viral infection and prevention immunopathology. 
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Figure 4 
 
 
 
Figure 2.4: CD169+ macrophages induce PD-L1 expression which inhibits 
immunopathology.	
	     44 
						
Figure 5 
 
 
Figure 2.5: CD169+ macrophages prevent severe immunopathology during chronic viral 
infection. 
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Supplementary	Figure	1	
 
 
 
 
 
Supplementary Figure 2.1: Gating strategy of CD169+ macrophages. 
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Supplementary Figure 2 
	
 
 
Supplementary Figure 2.2: Expression of CD169 on immune cells. 
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Virus-specific antibodies allow viral 
replication in the marginal zone, 
thereby promoting CD8+ T-cell 
priming and viral control
Vikas Duhan1,*, Vishal Khairnar1,*, Sarah-Kim Friedrich1, Fan Zhou1, Asmae Gassa1,2, 
Nadine Honke1, Namir Shaabani1, Nicole Gailus1, Lacramioara Botezatu3, 
Cyrus Khandanpour3, Ulf Dittmer4, Dieter Häussinger5, Mike Recher6, Cornelia Hardt1, 
Philipp A. Lang5,7,* & Karl S. Lang1,5,*
Clinically used human vaccination aims to induce specific antibodies that can guarantee long-
term protection against a pathogen. The reasons that other immune components often fail to 
induce protective immunity are still debated. Recently we found that enforced viral replication in 
secondary lymphoid organs is essential for immune activation. In this study we used the lymphocytic 
choriomeningitis virus (LCMV) to determine whether enforced virus replication occurs in the presence 
of virus-specific antibodies or virus-specific CD8+ T cells. We found that after systemic recall infection 
with LCMV-WE the presence of virus-specific antibodies allowed intracellular replication of virus in 
the marginal zone of spleen. In contrast, specific antibodies limited viral replication in liver, lung, and 
kidney. Upon recall infection with the persistent virus strain LCMV-Docile, viral replication in spleen was 
essential for the priming of CD8+ T cells and for viral control. In contrast to specific antibodies, memory 
CD8+ T cells inhibited viral replication in marginal zone but failed to protect mice from persistent viral 
infection. We conclude that virus-specific antibodies limit viral infection in peripheral organs but still 
allow replication of LCMV in the marginal zone, a mechanism that allows immune boosting during recall 
infection and thereby guarantees control of persistent virus.
Memory formation after antigen challenge is one of the most important hallmarks of the adaptive immune sys-
tem1; it protects the host from exposure to the original or a slightly modified pathogen1. Because of this known 
memory formation, vaccination with attenuated pathogens has been an important tool for preventing outbreaks 
of severe pathogen-mediated diseases. In the Western world, the World Health Organization recommends 
approximately 16 vaccinations2, 10 of which are antiviral.
Although virus-specific CD8+ T cells are known to contribute to the control of viral infections, all recom-
mended vaccinations are aimed at inducing antibodies against a pathogen3–7. For example, newly designed 
vaccines against HIV are intended to specifically activate HIV-specific CD8+ T cells8. However, to date, CD8+ 
T cell–mediated vaccines have failed to protect the host from persistent infection9. Therefore, the role of 
vaccine-induced virus-specific CD8+ T cells in long-term protection is still being debated10–12. To know in more 
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Virus-specific antibodies allow viral replication in the marginal zone, thereby 
promoting CD8+ T-cell priming and viral control 
	
Vikas Duhan, Vishal Khairnar, Sarah-Kim Friedrich, Fan Zhou, Asmae Gassa, Nadine 
Honke, Namir Shaabani, Nicole Gailus, Lacramioara Botezatu, Cyrus Khandanpour, Ulf 
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3.1 Abstract 
	
Clinically used human vaccination aims to induce specific antibodies that can 
guarantee long term protection against a pathogen. The reasons that other immune 
components often fail to induce protective immunity are still debated. Recently we found that 
enforced viral replication in secondary lymphoid organs is essential for immune activation. In 
this study we used the lymphocytic choriomeningitis virus (LCMV) to determine whether 
enforced virus replication occurs in the presence of virus-specific antibodies or virus-specific 
CD8+ T cells. We found that after systemic recall infection with LCMV-WE the presence of 
virus-specific antibodies allowed intracellular replication of virus in the marginal zone of 
spleen. In contrast, specific antibodies limited viral replication in liver, lung, and kidney. 
Upon recall infection with the persistent virus strain LCMV-Docile, viral replication in spleen 
was essential for the priming of CD8+ T cells and for viral control. In contrast to specific 
antibodies, memory CD8+ T cells inhibited viral replication in marginal zone but failed to 
protect mice from persistent viral infection. We conclude that virus-specific antibodies limit 
viral infection in peripheral organs but still allow replication of LCMV in the marginal zone, a 
mechanism that allows immune boosting during recall infection and thereby guarantees 
control of persistent virus. 
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3.2 Introduction 
Memory formation after antigen challenge is one of the most important hallmarks of 
the adaptive immune system125; it protects the host from exposure to the original or a slightly 
modified pathogen125. Because of this known memory formation, vaccination with attenuated 
pathogens has been an important tool for preventing outbreaks of severe pathogen-mediated 
diseases. In the Western world, the World Health Organization recommends approximately 
16 vaccinations126, 10 of which are antiviral.  
Although virus-specific CD8+ T cells are known to contribute to the control of viral 
infections, all recommended vaccinations are aimed at inducing antibodies against a 
pathogen127-131. For example, newly designed vaccines against HIV are intended to 
specifically activate HIV-specific CD8+ T cells132. However, to date, CD8+ T cell–mediated 
vaccines have failed to protect the host from persistent infection133. Therefore, the role of 
vaccine-induced virus-specific CD8+ T cells in long-term protection is still being debated134-
136. To know in more detail why several vaccines produce protective antibodies but vaccines 
against HIV and HCV could not do so far. The mechanistic understanding may help to 
generate new vaccines in future.  
Lymphocytic choriomeningitis virus (LCMV) is a non-cytopathic virus with the ability 
to persist. The acute strain LCMV-WE is usually controlled within 1 or 2 weeks, primarily by 
virus-specific CD8+ T cells. The functions of B cells against LCMV are important for long-
term control of the virus; however, CD8+ T cells are necessary for early control of LCMV. 
Infection with the LCMV-Docile strain leads to exhaustion of CD8+ T cells and therefore to 
persistence of the virus in the host119.  
Recently we found that antigen-presenting cells (CD169+ macrophages and CD11c+ 
dendritic cells) within the marginal zone specifically allow viral replication137. Enforced viral 
replication in the spleen is essential for activating the innate and adaptive immune systems138. 
It is still unknown whether enforced viral replication occurs after vaccination or after 
secondary infection and whether such replication is involved in immune boosting.  
In the study reported here we found that, after systemic recall, infection-specific 
antibodies allow intracellular replication of the virus in the marginal zone of the spleen but 
limit the replication of infectious virus in liver, lungs, and kidneys. Upon recall infection with 
the persistent virus strain LCMV-Docile, spleen-specific viral replication is associated with 
sufficient priming of CD8+ T cells and with viral control. In contrast to specific antibodies, 
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memory CD8+ T cells inhibit viral replication in the marginal zone thus fail to protect mice 
against persistent infection. 	  
3.3 Results 
3.3.1 Replication of LCMV in the marginal zone is associated with immune 
activation and viral control 
During primary viral infection, LCMV replicates in the marginal zone; this replication 
is essential for inducing adaptive immunity against the virus138. Histologic examination of the 
spleen on day 3 after infection with 2×104 plaque-forming units (PFU) of the acute strain 
LCMV-WE detected staining of LCMV along the marginal zone (Fig. 1A). This finding was 
associated with the induction of virus-specific CD8+ T cells (Fig. 1B) and the induction of 
LCMV-specific antibodies (Fig. 1C); these activities resulted in control of the virus within 8 
days (Fig. 1D). For early control of the virus, virus-specific CD8+ T cells are essential, as 
demonstrated by our finding that B2m–/– mice, which lack CD8+ T cells, could not control the 
virus in the circulation (Fig 1E). Jh–/– mice, which are deficient in B cells, controlled the virus 
in a manner similar to that of wild-type mice (Fig 1E).; this finding emphasizes that early 
control of LCMV-WE depends primarily on virus-specific CD8+ T cells. Therefore, we 
conclude that enforced viral replication leads to the priming of CD8+ T cells, which are 
necessary for early viral control, whereas B cells are most likely needed for long-term 
protection against LCMV139,140.   
3.3.2 Virus-specific antibodies, but not virus-specific CD8+ T cells, allow viral 
replication in the marginal zone 
 Recall viral infections often boost the existing immune response141. Whether an 
immune-response boost after a recall infection with LCMV requires viral replication and 
whether adaptive memory components allow replication of virus in the marginal zone remain 
unknown. To gain insights into this question we first infected mice with 200 PFU of LCMV-
WE and then 50 days later challenged them with 2×107 PFU of LCMV-WE. We could not 
detect any replication of virus within the marginal zone after recall infection (Fig. 2A). In line 
with this finding, no infectious virus was detected in any organ tested (Fig. 2B). These 
findings suggest that memory mice are well protected against LCMV recall infection.  
 Next we aimed to determine how various specific memory immune components limit 
viral replication in the marginal zone and peripheral organs. We infected wild-type (WT) 
mice with 2×106 PFU of LCMV-WE, and after 80 to 120 days of infection we transferred 
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various memory components from these infected mice into naïve WT mice. For control mice 
we transferred immune components from naïve mice to naïve mice. We focused on the 
transfer of serum for virus-specific antibodies, sorted splenic B cells, splenic CD8+ T cells, 
and splenic CD4+ T cells. For each memory component we transferred approximately 20% of 
the specific compartment of an LCMV-infected mouse (see Material and Methods). Two days 
after transfer we challenged mice with 2×106 PFU of LCMV-WE, and at days 1, 2, and 3 we 
analyzed viral distribution. Mice that received naïve immune components exhibited normal 
staining of LCMV in the marginal zone (Fig. 2C, supplementary Figure 1A). Both virus-
specific CD8+ T cells and antibodies allowed replication of virus at day 1 (Supplementary 
Figure 1A and 1B). After day 1, virus-specific CD8+ T cells inhibited the replication of virus 
in the marginal zone (Fig. 2C, Supplementary Figure 1A). Perforin deficient LCMV-
specific CD8+ T cells which were primed with recombinant LCMV (rLCMV) (see material 
and methods) did not effect the virus replication in marginal zone (Supplementary Figure 
1C) suggesting that direct cytotoxicity of virus-specific CD8+ T cells mediated by perforin 
killed virus-infected antigen-presenting cells in the marginal zone (Supplementary Figure 
1C). Transfer of virus-specific antibodies slightly reduced LCMV staining in the marginal 
zone but still allowed abundant replication at any time tested (Fig. 2C, Supplementary 
Figure 1A). Transfer of memory CD4+ T cells or memory B cells exerted no measurable 
influence on the replication of LCMV in the marginal zone (Supplementary Fig. 2A). 
Next we analyzed the role of virus-specific CD8+ T cells and virus-specific antibodies on 
the early distribution of virus in other organs. Virus-specific CD8+ T cells reduced infectious 
virus in the spleen alone after day 1 (Fig. 2D and Supplementary Figure 1B). Interestingly, 
although we found limited staining of virus-infected cells in the marginal zone, the levels of 
infectious LCMV were still easily detectable. This is probably due to the fact that virus-
specific CD8+ T cells target virus-bearing cells rather than free infectious virus. In peripheral 
organs, virus-specific CD8+ T cells exerted only a limited effect on viral replication (Fig. 2D 
and Supplementary Figure 1B). This finding suggests that virus-specific CD8+ T cells exert 
limited influence on the early replication of virus in the spleen, lymph nodes, liver, and lungs.  
 Like virus-specific CD8+ T cells, virus-specific antibodies reduced the amount of 
infectious virus in the spleen and lymph nodes but still allowed replication of virus (Fig. 2D, 
Supplementary Figure 1B). However, unlike virus-specific CD8+ T cells, virus-specific 
antibodies completely blunted the replication of virus in all peripheral organs tested (Fig. 2D, 
Supplementary Figure 1B). Memory B cells and CD4+ T cells exerted no significant effect 
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on the replication of virus in any of the organs tested (Supplementary Figure 2B), a finding 
implying that memory B and CD4+ T cells have no impact on the early distribution of virus. 
Therefore, we conclude that virus-specific antibodies allow the replication of virus in the 
splenic marginal zone but protect against the replication of virus in peripheral organs. Virus-
specific CD8+ T cells inhibit the replication of virus in the marginal zone but have limited 
impact on the replication of virus in peripheral organs. 
 Next we determined whether antigen-specific CD8+ T cells that were primed with 
Listeria monocytogenes behaved in the same manner as transferred virus-specific CD8+ T 
cells. We infected WT mice with L. monocytogenes expressing the glycoprotein of LCMV 
(LM-GP33) or with wild-type L. monocytogenes (LM-WT). Mice infected with LM-GP33 
generated LCMV GP33-specific CD8+ T cells (Fig. 3A and 3B). After 30 days the mice were 
infected with LCMV-WE. Control mice infected with LM-WT exhibited normal replication 
of virus in the marginal zone (Fig. 3C). In contrast, mice challenged with LM-GP33 did not 
exhibit viral staining in the marginal zone (Fig. 3C), a finding indicating inhibition of virus in 
the marginal zone by virus-specific CD8+ T cells. Virus-specific CD8+ T cells generated after 
LM-GP33 infection reduced the replication of infectious virus in lymph nodes and lungs; 
however, they did not influence the replication of virus in the liver (Fig. 3D).  
Therefore, we conclude that virus-specific antibodies allow viral replication in the 
marginal zone but suppress viral replication in other organs. Virus-specific CD8+ T cells 
suppress viral replication in the marginal zone but have limited influence on viral replication 
in peripheral organs. 
3.3.3 Virus-specific antibodies allow innate and adaptive immune activation 
	We found that virus-specific CD8+ T cells and virus-specific antibodies exert different 
effects on early viral distribution. Next we examined how differences in viral replication 
affect innate and adaptive immune activation. We transferred virus-specific antibodies or 
CD8+ T cells from memory mice into naïve C57BL/6 mice and infected them with LCMV-
WE. Virus-specific CD8+ T cells strongly reduced the induction of antiviral interferon type I 
(IFN-I) (Fig. 4A). The presence of virus-specific antibodies also reduced the IFN-I response 
(Fig. 4A) but to a lower extent than did virus-specific CD8+ T cells (Fig. 4A).  
Next we examined the antiviral CD8+ T cell response after LCMV infection. Transfer 
of virus-specific CD8+ T cells before infection exerted no effect on the total number of virus-
specific CD8+ T cells at day 10 after challenge with LCMV-WE (Fig. 4B upper panel, 4C). 
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Non-transferred endogenous virus-specific CD8+ T cells exhibited reduced activation in the 
presence of memory CD8+ T cells (Supplementary Figure 3). In contrast, in the presence of 
virus-specific antibodies the expansion of virus-specific CD8+ T cells was greater than that in 
mice receiving virus-specific CD8+ T cells or in mice receiving non-specific immune 
components (Fig. 4B upper panel and 4C). In addition, the production of IFN-g after in vitro 
restimulation was enhanced in splenocytes derived from mice treated with virus-specific 
antibodies (Fig. 4B middle panel and 4D). The total number of IFN-g–producing CD4+ T cells 
was also enhanced in the spleens of mice that had received virus-specific antibodies (Fig. 4B 
lower panel and 4E).  
We conclude that virus-specific antibodies allow innate immune activation and exert a 
positive effect on the induction of virus-specific CD8+ T cells. In contrast, the presence of 
virus-specific CD8+ T cells is not beneficial for immune activation upon challenge infection.  
3.3.4 Virus-specific antibodies protect against immunopathology and lead to 
control of virus 
Next we investigated the influence of virus-specific CD8+ T cells or virus-specific 
antibodies on overall outcome after infection with the persistent LCMV-Docile strain. Unlike 
LCMV-WE, LCMV-Docile induces persistent viral infection (Supplementary Figure 4A). 
We transferred virus-specific CD8+ T cells and virus-specific antibodies to naïve mice and 
infected them with 2 × 104 PFU of LCMV-Docile. As was true of challenge infection with the 
acute LCMV-WE strain, the presence of virus-specific antibodies allowed viral replication, 
and virus-specific CD8+ T cells almost inhibited viral replication in the splenic marginal zone 
(Fig. 5A). Unlike virus-specific CD8+ T cells, virus-specific antibodies totally blunted viral 
load in the peripheral organs (Supplementary Figure 4B). Transfer of virus-specific 
antibodies enhanced the priming and expansion of virus-specific CD8+ T cells (Fig. 5B). But 
transfer of virus-specific CD8+ T cells before infection abrogated the expansion of antigen 
specific CD8+ T cells (Fig. 5B). In line with these findings, our study showed that mice that 
received virus-specific antibodies before infection could eliminate LCMV-Docile, whereas it 
persisted in mice transferred with naïve immune components and in mice treated with virus-
specific CD8+ T cells (Fig. 5C). Virus-specific antibodies prevented elevation of serum 
alanine aminotransaminase (ALT) and lactate dehydrogenase (LDH) activity, which are signs 
of virus-induced immunopathology (Fig. 5D). Interestingly, the transfer of virus-specific 
CD8+ T cells reduced immunopathology, a finding that is in line with reduced activation of 
CD8+ T cells. Next we subjected mice that had been vaccinated with LM-GP33 to infection 
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with LCMV-Docile. As in our transfer experiments, LM-GP33–vaccinated mice could not 
eliminate LCMV-Docile (Fig. 5E).  
Next we examined whether the priming of CD8+ T cells in the presence of virus-
specific antibodies was essential for the control of LCMV-Docile. We transferred virus-
specific antibodies into B2m−/− mice, which lack CD8+ T cells. In the absence of CD8+ T 
cells, virus-specific antibodies did not control LCMV-Docile infection (Fig. 5F), a finding 
suggesting that secondary CD8+ T-cell activation is essential for viral control after challenge 
infection. 
3.3.5 Virus-specific antibodies enhance priming and expansion of CD8+ T cells 
We found that the priming and expansion of virus-specific CD8+ T cells was highly 
improved in the presence of virus-specific antibodies. Virus-specific antibodies, which were 
used for the transferred experiments showed only slight neutralization capacity in in-vitro 
assay (Fig. 6A). To gain insights into the mechanism of action of virus-specific antibodies, 
we first determined whether these antibodies simply reduced the amount of free infectious 
virus immediately after infection. To do so, we examined CD8+ T-cell activation after 
infection with various doses of LCMV-Docile with or without additional treatment with 
LCMV-specific antibodies (LCMV-Ab). Viral control was possible after infection with 200 
PFU, 1000 PFU, or 20,000 PFU in the presence of virus-specific antibodies (Fig. 6B). In the 
absence of these antibodies, maximal CD8+ T-cell priming was achieved with an infectious 
dose of 200 PFU LCMV-Docile (Fig. 6C, D and E). In the presence of virus-specific 
antibodies the priming of CD8+ T cells was even higher than after infection of 200 PFU (Fig. 
6D and E), a finding suggesting that additional mechanisms other than reducing the infectious 
dose contribute to enhancements in the priming of CD8+ T cells. 
3.3.6	 Immune activation in the presence of virus-specific antibodies is essential 
for controlling persistent infection 
 We found that the transfer of virus-specific antibodies leads to strong priming of CD8+ 
T cells, which is associated with viral control and limited immunopathology. Recently we 
found that the IFN-I inhibitor Usp18 is highly expressed in CD169+ marginal zone 
macrophages and dendritic cells and is therefore crucial for viral replication in these cells 
reside in spleen and lymph nodes137,138. The absence of either marginal zone macrophages or 
Usp18 limits viral replication, and this limitation is associated with the absence of antiviral 
innate or adaptive immune responses137,138. To determine whether Usp18-dependent viral 
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replication in marginal zone macrophages is also necessary for the activation of CD8+ T cells 
after secondary antigen challenge, we next transferred virus-specific antibodies to WT and 
CD169-DTR mice, in which specific CD169+ marginal zone macrophages can be depleted by 
injecting diphtheria toxin, and infected them with LCMV-Docile. In the absence of marginal 
zone macrophages, virus-specific CD8+ T-cell expansion (Fig. 7A) and IFN-g production by 
CD8+ T cells (Fig. 7B) and CD4+ T cells (Fig. 7C) were reduced. This lack of a sufficient 
virus-specific CD8+ T-cell response leads to viral persistence (Fig. 7D).  
Furthermore, to examine the role of Usp18 we transferred virus-specific antibodies to 
WT and Usp18–/– mice and infected the mice with LCMV-Docile. In absence of Usp18, viral 
replication was impaired in splenic marginal zone macrophages (Fig. 8A and supplementary 
Figure 5). The absence of Usp18 limited the expansion of virus-specific CD8+ T cells (Fig. 
8B) and reduced IFN-g production by CD8+ T cells (Fig. 8C) and CD4+ T cells (Fig. 8D). The 
lack of innate and adaptive immune activation in the absence of Usp18 was associated with a 
problem in viral clearance (Fig. 8E). This finding suggests that, in the presence of virus-
specific antibodies, Usp18 is necessary for viral replication in marginal zone macrophages 
and also enhances the priming of virus-specific CD8+ T cells.  
3.4 Discussion 
In the study reported here, we found that virus-specific antibodies limit the quantity of 
infectious virus in peripheral organs but still allow viral replication in the marginal zone. This 
specific distribution of virus after challenge with infection is beneficial for innate and 
adaptive immune activation; it limits immunopathology and leads to viral control.  
Currently the World Health Organization (WHO) recommends 10 antiviral 
vaccinations, which clearly protect the vaccinated host from infection with the live pathogen. 
Natural viral infection induces plasma cells, which produce virus-specific antibodies142. 
Although specific antibodies mainly target infectious virus particles, virus-specific CD8+ T 
cells can directly suppress viral replication in infected cells143. Currently available 
vaccinations induce measurable antibodies against the pathogen but often fail to induce virus-
specific CD8+ T cells144. Some reports suggest that, after secondary infection or vaccination, 
contact with the virus will further activate the immune system, which then induces protective 
T-cell immunity145-147. Indeed, in the Friend virus model, antibodies can enhance the virus-
specific CD8+ T-cell response148. The results of our study show that specific antibodies block 
viral replication within peripheral organs within the first days after infection but still allow 
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enforced viral replication in lymphoid organs. We found that the presence of antibodies 
limited viral replication in the liver and induced more-efficient antiviral CD8 T cells. The 
organ-specific antiviral capacity of virus-specific antibodies may be due to differential 
expression of Fc receptors in different organs. One way to induce such antiviral mechanisms 
could be via Fc receptor III (CD16), which either tracks virus into various vesicular 
compartments or induces antiviral activity149. In addition, complement may track virus into a 
separate compartment150.  Further studies remain to be done to analyse the mechanism of Fc 
receptors on antiviral activity in macrophages. The production of antiviral cytokines and 
virus-specific CD8+ T cells could be induced and could lead to rapid control of recall 
infection. Therefore, we suggest that antibodies are, at least for some viruses, much more 
potent memory components than are CD8+ T cells.   
Immunological memory against hepatitis C virus (HCV) is a challenge to the immune 
system, and the generation of vaccines against HCV has failed to date151. One reason for this 
failure is that the virus can mutate quickly during infection; when this happens, the existing 
immunological memory is no longer protective152. On the basis of our findings, we suggest 
that a good vaccine should still allow some viral replication in certain secondary lymphoid 
niches but should also inhibit the spread of virus to the susceptible organ. We suggest that, 
because HCV replication in antigen-presenting cells is very limited or almost absent, it is 
probably impossible for CD8+ T cells to be primed in the presence of virus-specific 
antibodies. This hypothesis may at least partially explain the failure of HCV vaccines. 
Recently it was shown that preexposure to HCV antigen induces the production of CD8+ T 
cells, which suppress the immune response after viremic infection with HCV153. Although the 
authors of that study explained this phenomenon by the presence of regulatory T cells, it is 
possible that rapid inhibition of viral replication may limit the draining of HCV antigen to 
secondary lymphoid organs and can thereby limit the induction of a protective antiviral 
immune response. 
Of course, we may question whether the mechanisms we found for LCMV are also 
relevant to HIV. HIV-specific antibodies do not induce protective immunity154, and cellular 
immunity does not lead to a protective immune response upon challenge infection155. The fact 
that HIV induces marginal zone atrophy and marginal zone lymphoma156,157 and the fact that 
CD4+ T cells can be activated in the marginal zone and are the main target cells of HIV 
infection137 suggest that the marginal zone is a niche in which activated CD4+ T cells are 
easily infected. In light of our findings, we suggest that allowing HIV replication in the 
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marginal zone of the spleen may in this special case be a disadvantage, because activated 
CD4+ T cells are located mainly within the marginal zone. Although this hypothesis could 
explain the difficulties in generating an HIV vaccine154, the generation of more data from HIV 
animal models is necessary before we can draw conclusions about the relationship between 
antibodies, CD8+ T cells, and HIV replication in the marginal zone.  
In conclusion, we found that specific antibodies are much more potent than CD8+ T 
cells in protecting mice against viruses that are prone to persistence because these antibodies 
blunt the replication of virus in peripheral organs but allow replication of virus in the 
marginal zone, thereby leading to effective immune priming. 
3.5 Methods 
3.5.1 Mice 
CD169-DTR, Jh−/−, Prf1−/−, and B2m−/− mice were maintained on a C57BL/6 background. 
CD45.1 congenic mice were used as wild type mice to track the cells. Usp18−/− mice were 
maintained on a mixed background, and mice were directly compared to littermate controls. 
KL25 mice, which express the immunoglobulin heavy chain of LCMV-neutralizing 
antibodies were maintained on a CD45.1 background and serum of LCMV infected KL25 
mice was used as positive control for in vitro virus neutralization assay. This study was 
approved by the Nordrhein Westfalen Landesamt für Natur, Umwelt und Verbraucherschutz 
(Recklinghausen, Germany) and carried out in accordance with the German law for animal 
protection. All the experimental protocols were approved by the Nordrhein Westfalen 
Landesamt für Natur, Umwelt und Verbraucherschutz (Recklinghausen, Germany) or with the 
institutional guidelines of the Ontario Cancer Institute of the University Health Network and 
at McGill University. 
3.5.2	 Pathogens and plaque assays 
The LCMV-WE and LCMV-Docile strains were originally obtained from F. Lehmann-
Grube (Heinrich Pette Institute, Hamburg, Germany) and were propagated on L929 cells, 
MC57 cells, or both. Mice were infected intravenously with various doses of LCMV. LCMV 
viral titers were detected by plaque-forming assays on MC57 fibroblasts, as previously 
described158. A replication-deficient recombinant LCMV (rLCMV; kindly provided by 
Pinschewer) that express the mutated form of LCMV-GP but still has antigenic properties was 
produced according to standard protocols90 and was injected intravenously into mice. The 
recombinant Listeria monocytogenes expressing the epitope of glycoprotein 33–41 of LCMV 
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(LM-GP33) and wild-type Listeria monocytogenes (LM-WT) were grown in brain-heart 
infusion medium diluted in phosphate buffered saline (PBS) and were injected intravenously 
into mice. 
3.5.3 Memory cells and immune serum isolation and transfer 
Six- to 8-week-old C57BL/6 naïve mice were infected intravenously with 2 × 106 PFU of 
LCMV-WE. After 80 to 120 days of infection, immune components were isolated from these 
memory mice. LCMV-immune serum was collected and pooled from a group of mice, and 
virus-free serum was used to inject intravenously into mice for all experiments. CD8+ T cells, 
CD4+ T cells, and B220+ cells were isolated from spleen of memory mice with magnetic-
activated cell sorting (MACS) isolation kit, according to the manufacturer’s protocol 
(Miltenyi Biotec, Germany). Serum and memory-cell transfers were performed 2 days before 
the infection. Mice were injected once intravenously with 300 µl of immune serum, 5 × 106 
memory CD8+ T cells, 1 × 107 memory CD4+ T cells, or 1 × 107 memory B cells. Prf1−/− mice 
were infected with 2 × 105 PFU of rLCMV and for control group C57BL/6 naïve mice got 2 × 
105 PFU of rLCMV infection. After 30 days spleens of these memory mice were used as 
donors for LCMV-specific memory CD8+ T cells. 
3.5.4 Histologic analysis 
Histologic analyses of snap-frozen tissues were performed with mouse monoclonal 
antibodies to LCMV nucleoprotein (NP; made in house), CD169 (MCA884F; AbD Serotec, 
Germany), or CD45R/B220 (RA3-6B2; eBioscience, Germany). Red pulp macrophages were 
stained with F4/80 (BM8; eBiosciences). 
3.5.5 Enzyme-linked immunosorbent assays 
Interferon-alpha (IFN-α) enzyme-linked immunosorbent assays (ELISA) were performed 
according to the manufacturer’s protocol (PBL Interferon Science, Germany). 
3.5.6 Flow cytometry 
The Tetramer Facility of National Institutes of Health (NIH) provided LCMV-GP33 
tetramer. Cells were stained with allophycocyanin (APC)-labeled GP33 MHC class I tetramer 
(GP33/H-2Db) for 15 minutes at 37 °C. After incubation, the samples were stained with anti-
CD8 (clone 53–6.7; eBioscience) or anti-CD4 (clone GK1.5; eBioscience) antibodies for 30 
minutes at 4 °C. Absolute numbers of GP33-specific CD8+ T cells were calculated with 
fluorescent beads (BD Biosciences) by using fluorescence-activated cell sorting (FACS). For 
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measurement of intracellular IFN-γ, cells were fixed with 2% formaldehyde in PBS for 10 
minutes, permeabilized with 1% saponin in FACS buffer at room temperature, and stained 
with anti–IFN-γ antibody for 30 minutes at 4 °C (clone XMG1.2; eBioscience). All stained 
cells were analysed with a FACS Fortessa (BD Biosciences) flow cytometer, and data were 
analysed with FlowJo software. 
3.5.7 ALT and LDH measurement 
The activity of ALT and LDH was measured in the Central Laboratory, University 
Hospital Essen, Germany. 
3.5.8 LCMV neutralization assay 
The neutralizing capability of serum was measured with plaque-forming assays according 
to a previously published protocol158. 
3.5.9 Statistical analysis 
Data are expressed as means ± SEM. Student’s t-test was used to detect statistically 
significant differences between groups. Significant differences between several groups were 
detected by one-way analysis of variance (ANOVA) with the Bonferroni or Dunnett post hoc 
test. The level of statistical significance was set at P < 0.05. 
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3.8 Figure Legend 
3.8.1 Figure 1: Replication of lymphocytic choriomeningitis virus (LCMV) in the 
marginal zone is associated with immune activation and viral control  
C57BL/6 mice were infected intravenously with 2 × 104 plaque-forming units (PFU) of 
LCMV strain WE (LCMV-WE) and were analysed for various parameters. (A) 
Representative immunofluorescence of spleen after 3 days of infection, stained for LCMV 
nucleoprotein (red), marginal zone macrophages (CD169, green), and red pulp 
macrophages (F4/80, blue). One slide representative of 6 slides is shown. Scale bar, 
200 µm. (B) Total number of LCMV-specific T cells in the blood that were positive for the 
MHC class I tetramer of the glycoprotein of LCMV (Tet-GP33+) and for CD8 (CD8+), as 
measured by fluorescence-activated cell sorting (FACS) at the indicated days after 
infection (n = 3–7). (C) LCMV GP-specific antibodies in serum were analysed by enzyme-
linked immunosorbent assay (ELISA) on various days after infection (n = 4). (D) Viral 
titers from spleen and inguinal lymph nodes were analysed by plaque-forming assay at the 
indicated time points after infection (n = 3). (E) Viral titers in serum of wild type 
(WT), B2m−/−, and Jh−/− mice on various days after infection (n = 4). Horizontal dotted 
lines designate the detection limit. Data are shown as mean ± SEM. 
3.8.2 Figure 2: Virus-specific antibodies, but not virus-specific CD8+ T cells, 
allow viral replication in the marginal zone 
(A) Naïve (non-memory) and memory C57BL/6 mice were infected intravenously with 2 
× 107 plaque-forming units (PFU) of lymphocytic choriomeningitis virus strain WE (LCMV-
WE). After day 1 spleen sections were stained for LCMV nucleoprotein (red), marginal zone 
macrophages (CD169, green), and red pulp macrophages (F4/80, blue). One slide 
representative of 4 slides is shown. Scale bar, 100 µm. (B) Viral titers from spleen, inguinal 
lymph nodes (LN), liver, and lungs of naïve and memory C57BL/6 mice infected 
intravenously with 2 × 107 PFU of LCMV-WE, as measured on day 1 (n = 4–6). (C, D) 
C57BL/6 naïve mice were injected separately with naïve CD8+ T cells and non-specific 
antibodies (naïve serum) collected from naïve mice, and with LCMV-specific CD8+ T cells 
and LCMV-specific antibodies (immune serum) collected from memory mice. After 2 days 
all mice were infected with 2 × 106 PFU of LCMV-WE. (C) Representative 
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immunofluorescence of spleen after 3 days of viral infection, stained for LCMV 
nucleoprotein (red) and marginal zone macrophages (CD169, green). One slide representative 
of 6 slides is shown. Scale bar, 200 µm. (D) Viral titers from spleen, inguinal lymph node 
(LN), liver, and lungs after 3 days of viral infection (n = 6–7). Horizontal dotted lines 
designate the detection limit. Data are shown as mean ± SEM and are pooled from 2 or 3 
independent experiments. 
3.8.3 Figure 3: Inhibition of viral replication in splenic marginal zone of mice 
primed with recombinant Listeria monocytogenes expressing the glycoprotein of 
LCMV 
C57BL/6 naïve mice were infected with 1 × 106 colony-forming units (CFU) of Listeria 
monocytogenes expressing the glycoprotein of lymphocytic choriomeningitis virus (LM-
GP33), and control mice were infected with a lower dose (1 × 104 CFU) of wildtype L. 
monocytogenes (LM-WT) as higher dose is lethal for mice. After 30 days mice were injected 
with 2 × 106 PFU of LCMV-WE. (A) Fluorescence-activated cell sorting (FACS) plots 
showing the frequency of T cells that were positive for the MHC class I tetramer of the 
glycoprotein of LCMV (Tet-GP33+) and for CD8 (CD8+) in the total number of CD8+ T cells 
in the blood at indicated days after LM-GP33 infection. (B) Graph showing the total number 
of Tet-GP33+ CD8+ T cells in blood on various days after LM-GP33 infection (n = 6). (C) 
Immunohistochemical analysis of spleens from LM-GP33–primed mice after 3 days of 
LCMV strain WE (LCMV-WE) infection, showing LCMV nucleoprotein (red) and marginal 
zone macrophages (CD169, green). Scale bar, 200 µm (n = 5). (D) Viral titers from spleen, 
inguinal LN, liver, and lungs after 3 days of LCMV-WE infection (n = 5). Horizontal dotted 
lines designate the detection limit. Data are shown as mean ± SEM and are pooled from 2 
independent experiments. 
3.8.4 Figure 4. Virus-specific antibodies allow innate and adaptive immune 
activation 
C57BL/6 naïve mice were injected separately with naïve CD8+ T cells and non-specific 
antibodies (naïve serum) collected from naïve mice, and with lymphocytic choriomeningitis 
(LCMV)-specific CD8+ T cells and LCMV-specific antibodies (immune serum) collected 
from memory mice. After 2 days all mice were infected with 2 × 106 plaque-forming units 
(PFU) of LCMV strain WE (LCMV-WE). (A) Levels of interferon (IFN)-α were measured in 
the serum by enzyme-linked immunosorbent assay (ELISA) after 2 days of infection (n = 6). 
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(B) Representative fluorescence-activated cell sorting (FACS) plots showing the frequency of 
LCMV-specific T cells in the spleen that were positive for the MHC class I tetramer of the 
glycoprotein of LCMV (Tet-GP33+) and for CD8 (CD8+) in the total number of CD8+ T cells 
in the spleen (upper plots). Frequency of IFN-γ+ CD8+ T cells (middle plots) and IFN-γ+ 
CD4+ T cells (lower plots) in the spleen after in vitro stimulation with LCMV GP33 and 
LCMV GP64 peptide respectively after 10 days of viral infection. (C) Total number of 
LCMV-specific Tet-GP33+ CD8+ T cells in the spleen after 10 days of viral infection (n = 4–
6). (D) Total number of IFN-γ+ CD8+ T cells in the spleen after 10 days of viral infection and 
after in vitro stimulation with LCMV GP33 peptide for 5 hours (n = 4–6). (E) Total number 
of IFN-γ–producing CD4+ T cells in the spleen after 10 days of viral infection and after in 
vitro stimulation with LCMV GP64 peptide for 5 hours (n = 3–6). Data are shown as mean ± 
SEM and are pooled from 2 or 3 independent experiments. *P < 0.05; **P < 0.01; ***P < 
0.001 (Student’s t-test). 
3.8.5 Figure 5. Virus-specific antibodies protect against immunopathology and 
lead to control of virus 
C57BL/6 naïve mice were injected separately with naïve CD8+ T cells and non-specific 
antibodies (naïve serum) collected from naïve mice, and with lymphocytic choriomeningitis 
virus (LCMV)-specific CD8+ T cells and LCMV-specific antibodies (immune serum) 
collected from memory mice. After 2 days all mice were infected with 2 × 104 plaque forming 
units (PFU) of LCMV-Docile. (A) Representative immunofluorescence of spleen after 3 days 
of infection, stained for LCMV nucleoprotein (red) and marginal zone macrophages (CD169, 
green). One slide representative of 3 slides is shown. Scale bar, 200 µm. (B) Total number of 
LCMV-specific T cells in the spleen that were positive for the MHC class I tetramer of the 
glycoprotein of LCMV (Tet-GP33+) and for CD8 (CD8+) after 10 days of viral infection (n = 
4–7). (C) Viral titers from spleen, inguinal LN, liver, kidney, and lungs after 10 days of viral 
infection (n = 7–10). (D) Levels of alanine aminotransaminase (ALT) and lactate 
dehydrogenase (LDH) in serum were measured after 10 days of viral infection (n = 7–10). (E) 
C57BL/6 mice primed with Listeria monocytogenes expressing the glycoprotein of 
lymphocytic choriomeningitis virus (LM-gp33) were infected with 2 × 106 PFU of LCMV-
Docile. After 10 days viral titers were measured in various organs, as indicated (n = 5–8). (F) 
C57BL/6 and B2m−/− mice were treated with virus-specific antibodies or were left untreated. 
After 2 days all mice were infected with 2 × 104 PFU of LCMV-Docile. Viral titers from 
spleen, inguinal LN, liver, kidney, and lungs were measured after 10 days of viral infection (n 
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= 3–4). Horizontal dotted lines designate the detection limit. Data are shown as mean ± SEM 
and are pooled from 2 or 3 independent experiments. *P < 0.05; **P < 0.01; ***P < 0.001 
(Student’s t-test). 
3.8.6 Figure 6: Virus-specific antibodies enhance priming and expansion of 
CD8+ T cells 
(A) Graph showing the total neutralizing antibodies in naïve serum (WT, naive), serum 
from memory C57BL/6 mice (WT, LCMV) on day 100 and from KL25 mice (KL25, LCMV) 
on day 10 after infection with 2 × 106 PFU of LCMV-WE and determined by in vitro 
neutralization assay (n = 4–5). (B–E) Naïve C57BL/6 mice were injected with non-specific 
antibodies or LCMV-specific antibodies. Mice treated with non-specific antibodies were 
infected separately with 2 × 102, 1 × 103, 5 × 103, or 2 × 104 PFU of LCMV-Docile. Mice 
treated with LCMV-specific antibodies were infected with 2 × 104 PFU of LCMV-Docile. (B) 
Viral titers in various organs after 10 days of viral infection (n = 6). (C) FACS plots 
representing the frequency of LCMV-specific Tet-GP33+ CD8+ T cells in blood (upper plots) 
and spleen (middle plots) after 10 days of infection. Lower plots show the frequency of 
interferon (IFN)-γ+ CD8+ T cells in spleen after 10 days of viral infection and in vitro 
stimulation with LCMV GP33 peptide (n = 6–9). (D) Total number of LCMV-specific Tet-
GP33+ CD8+ T cells in spleen after 10 days of viral infection (n = 6–9). (E) Total number of 
IFN-γ+ CD8+ T cells in spleen after in vitro stimulation with LCMV GP33 peptide on day 10 
of infection (n = 6–9). Horizontal dotted lines designate the detection limit. Data are shown as 
mean ± SEM and are pooled from 2 or 3 independent experiments. *P < 0.05; **P < 0.01; 
***P < 0.001 (Student’s t-test). 
3.8.7 Figure 7: Immune activation in the presence of virus-specific antibodies is 
essential for controlling persistent viral infection 
Naïve C57BL/6 mice and CD169-DTR mice were treated with diphtheria toxin (30 µg/kg) 
on day -3 and day 2 and were injected with lymphocytic choriomeningitis (LCMV)-specific 
antibodies on day -2. One group of C57BL/6 mice was injected with non-specific antibodies 
on day -2. All mice were infected with 2 × 104 plaque-forming units (PFU) of LCMV-Docile 
on day 0. Ten days later mice were evaluated for various parameters. (A) Total number of 
LCMV-specific T cells in spleen that were positive for the MHC class I tetramer of the 
glycoprotein of LCMV (Tet-GP33+) and for CD8 (CD8+) (n = 6). (B) Total number of 
interferon (IFN)-γ+ CD8+ T cells in spleen was determined after in vitro stimulation with or 
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without LCMV GP33 peptide for 5 hours (n = 6). (C) Total number of IFN-γ producing CD4+ 
T cells in spleen after in vitro stimulation with or without LCMV GP64 peptide for 5 hours (n 
= 6). (D) Viral titers in spleen, inguinal lymph nodes (LN), liver, kidney, and lungs were 
measured after 10 days of viral infection (n = 6). Data are shown as mean ± SEM and are 
pooled from 2 independent experiments. *P < 0.05; **P < 0.01 and ***P < 0.001 (Student’s t-
test). 
3.8.8 Figure 8: Immune activation in the presence of virus-specific antibodies is 
Usp18 dependent 
Lymphocytic choriomeningitis virus (LCMV)-specific antibodies were injected into 
Usp18−/− mice and littermate control mice. Non-specific antibodies were injected into 
littermate control mice to form a control group. Mice were challenged with LCMV-Docile. 
(A) Immunohistochemical analysis of spleen showing LCMV nucleoprotein (red), marginal 
zone macrophages (CD169, green), and follicular B cells (B220, blue) after 1 day of infection 
with 2 × 106 plaque-forming units (PFU) of LCMV-Docile (n = 3). Scale bar, 200 µm. (B–E) 
Mice were infected with 2 × 104 PFU of LCMV-Docile and were evaluated for various 
parameters after 10 days of infection. (B) Total number of LCMV-specific T cells in the 
spleen that were positive for the MHC class I tetramer of the glycoprotein of LCMV (Tet-
GP33+) and for CD8 (CD8+) (n = 5–8). (C) Total number of interferon (IFN)-γ+ CD8+ T cells 
in the spleen was determined after in vitro stimulation with or without LCMV GP33 peptide 
for 5 hours (n = 5–8). (D) Total number of IFN-γ producing CD4+ T cells after in vitro 
stimulation with or without LCMV GP64 peptide for 5 hours in spleen (n = 5–8). (E) Viral 
titers from spleen, inguinal lymph nodes (LN), liver, kidneys, and lungs (n = 7–8). Data are 
shown as mean ± SEM and are pooled from 2 or 3 independent experiments. *P < 0.05; **P < 
0.01; ***P < 0.001 (Student’s t-test). 
3.9 Supplementary Figures 
3.9.1 Figure 1: Virus-specific antibodies, but not virus-specific CD8+ T cells, 
allow viral replication in the marginal zone 
(A, B) C57BL/6 naïve mice were injected with naïve CD8+ T cells, non-specific 
antibodies (naïve serum), lymphocytic choriomeningitis (LCMV)- specific CD8+ T cells, or 
LCMV-specific antibodies (immune serum). After 2 days all mice were infected with 2×106 
plaque-forming units (PFU) of LCMV strain WE (LCMV-WE). (A) Representative 
immunofluorescence of spleen is shown after day 1 and 2 of infection, stained for LCMV 
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nucleoprotein (red) and marginal zone macrophages (CD169, green). One slide representative 
of 3 slides is shown. (B) Viral titers from spleen, inguinal lymph nodes (LN), liver, and lungs 
after 1 or 2 days of viral infection (n = 3). (C,D) Memory CD8+ T cells isolated from 
C57BL/6 memory and prf1–/– memory mice were injected to CD45.1 (wild-type; WT) naïve 
mice. One CD45.1 (wild-type; WT) group received naïve CD8+ T cells as control. After 2 
days mice were injected with 2×104 PFU of LCMV-WE. (C) Representative 
immunofluorescence of the spleen is shown after 3 days of infection, stained for LCMV 
nucleoprotein (red), marginal zone macrophages (CD169, green) and transferred CD8+ T cells 
(CD45.2, blue). One slide representative of 3 experiments is shown. (D) Graph shows the 
viral titers in the spleen after 3 days of infection. Horizontal dotted lines designate the 
detection limit. Data are shown as mean ± SEM. *P < 0.05; **P < 0.01; ***P<0.001 
(Student’s t-test). 
3.9.2 Figure 2: Memory CD4+ T cells and memory B cells has no effect on viral 
replication in the marginal zone 
C57BL/6 naïve mice were injected with memory B220+ B cells and memory CD4+ T cells 
isolated from memory mice. One group of mice was left untreated. After 2 days all mice were 
infected with 2×106 plaque-forming units (PFU) of lymphocytic choriomeningitis virus strain 
WE (LCMVWE). (A) Representative immunofluorescence in spleen after 3 days of infection, 
stained for LCMV nucleoprotein (red), marginal zone macrophages (CD169, green), and red 
pulp macrophages (F4/80, blue). One representative slide of 3 is shown. (B) Viral titers from 
various organs after 3 days of viral infection (n = 3). Horizontal dotted lines designate the 
detection limit. Data are shown as mean ± SEM.  
3.9.3 Figure 3: Memory CD8+ T cells reduce the expansion of endogenous CD8+ 
T cells 
CD45.1 (wild-type; WT) congenic naïve mice were injected with lymphocytic 
choriomeningitis virus (LCMV)-specific CD8+ T cells isolated from C57BL/6 memory mice. 
One group of mice was injected with naïve CD8+ T cells isolated from naïve C57BL/6 mice. 
After 2 days all mice were infected with 2×106 plaque-forming units (PFU) of LCMV strain 
WE (LCMV-WE). Total numbers of endogenous and exogenous T cells positive for the MHC 
class I tetramer of the glycoprotein of LCMV (Tet-GP33+) and for CD8 (CD8+) in the spleen 
were determined after 10 days of infection (n = 3-4). Data are shown as mean ± SEM. *P < 
0.05 (Student’s t-test). 
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3.9.4 Figure 4: Virus-specific antibodies inhibit persistent LCMV-Docile 
replication in peripheral organs 
(A) C57BL/6 naïve mice were infected separately with 2×104 plaque-forming units (PFU) 
of lymphocytic choriomeningitis virus strain WE (LCMVWE) and LCMV-Docile. Graph 
shows viral titers in serum on indicated days. (B) C57BL/6 naïve mice were injected with 
naïve CD8+ T cells, nonspecific antibodies (naïve serum), LCMV-specific CD8+ T cells, or 
LCMV-specific antibodies (immune serum). After 2 days all mice were infected with 2×104 
PFU of LCMV-Docile. Graph shows viral titers in spleen, inguinal lymph nodes, liver, and 
lungs after 3 days of infection. Horizontal dotted lines designate the detection limit. Data are 
shown as mean ± SEM. 
 
3.9.5 Figure 5: Usp18 promotes LCMV replication 
Usp18–/– mice and littermate control naïve mice (wild-type; WT) were infected with 2×106 
plaque-forming units (PFU) of lymphocytic choriomeningitis strain Docile (LCMV-Docile). 
Graph shows viral titers in spleen after 1 day of infection (n = 4). Horizontal dotted lines 
designate the detection limit. Data are shown as mean ± SEM. ***P < 0.001 (Student’s t-test). 
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Figure 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1: Replication of lymphocytic choriomeningitis virus (LCMV) in the marginal 
zone is associated with immune activation and viral control. 
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Figure 2 
 
 
 
Figure 3.2: Virus-specific antibodies, but not virus-specific CD8+ T cells, allow viral 
replication in the marginal zone. 
	     72 
						
Figure 3 
 
 
 
 
Figure 3.3: Inhibition of viral replication in splenic marginal zone of mice primed with 
recombinant Listeria monocytogenes expressing the glycoprotein of LCMV.  
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Figure 4 
 
Figure 3.4: Virus-specific antibodies allow innate and adaptive immune activation. 
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Figure 5 
 
 
 
Figure 3.5: Virus-specific antibodies protect against immunopathology and lead to 
control of virus. 
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Figure 6 
 
Figure 3.6: Virus-specific antibodies enhance priming and expansion of CD8+ T cells. 
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Figure 7 
 
 
 
Figure 3.7: Immune activation in the presence of virus-specific antibodies is essential for 
controlling persistent viral infection.  
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Figure 8 
 
 
Figure 3.8: Immune activation in the presence of virus-specific antibodies is Usp18 
dependent. 
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Supplementary Figure 1 
 
Supplementary Figure 3.1: Virus-specific antibodies, but not virus-specific CD8+ T cells, 
allow viral replication in the marginal zone. 
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Supplementary Figure 2 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure 3.2: Memory CD4+ T cells and memory B cells has no effect on 
viral replication in the marginal zone. 
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Supplementary Figure 3 
 
 
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Supplementary Figure 3.3: Memory CD8+ T cells reduce the expansion of endogenous 
CD8+ T cells. 
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Supplementary Figure 4 
 
	
	
	
	 	
	
	
	
	
Supplementary Figure 3.4: Virus-specific antibodies inhibit persistent LCMV-Docile 
replication in peripheral organs. 
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Supplementary Figure 5 
 
 
	
	
	
	
	
	
	
	
	
	
	
 
 
 
Supplementary Figure 3.5: Usp18 promotes LCMV replication. 
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Supplementary	Figure	5:	Usp18	promotes	LCMV	replica;on.	
Usp18	–/–	 	mice	and	 liMermate	control	naïve	mice	 (wild-type;	WT)	were	 infected	with	2×106	plaque-forming	units	 (PFU)	of	 lymphocy>c	
choriomeningi>s	strain	Docile	 (LCMV-Docile).	Graph	shows	viral	>ters	 in	spleen	a[er	1	day	of	 infec>on	(n	=	4).	Horizontal	doMed	 lines	
designate	the	detec>on	limit.	Data	are	shown	as	mean	±	SEM.	***P	<	0.001	(Student’s	t-test).	
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In these two studies, we found the roles of splenic metallophilic marginal zone macrophages 
(CD169+ macrophages) during primary and secondary infection of LCMV. Recently it was 
explained that CD169+ macrophages experience early virus replication in secondary lymphoid 
organs during systemic VSV infection117. In this study using LCMV infection, we did not see 
significant effect of CD169+ macrophages on early virus replication in secondary lymphoid 
organs. This could be explained by the involvement of dendritic cells  in early virus 
replication of LCMV116.  But CD169+ macrophages present in spleen and lymph node 
contributed for sustained production of systemic IFN-I. This contribution to IFN-I production 
lead to activation of antiviral effector functions in lymphoid and non-lymphoid organs that 
inhibited virus replication. Lack of CD169+ macrophages led to tremendous virus replication 
in liver hepatocytes.  
Priming and expansion of virus specific CD8+ T cells was found to be similar in absence of 
CD169+ macrophages during LCMV infection. But activation status explained by surface 
molecules expression and functional effectors molecules of virus specific CD8+ T cells were 
significantly high in mice deficient with CD169+ macrophages. Due to IFN-I signaling in WT 
mice, expression of PD-L1 in liver was enhanced.  PD-L1 is a negative regulator of T-cell 
effector functions. Presence of CD169+ macrophages maintained a balanced CD8+ T cells 
effector functions, which led to clearance of virus with minimal pathology. Due to lack of 
CD169+ macrophages, IFN-I production was impaired that led to low level of PD-L1 
expression in liver. Lack of IFN-I signaling caused virus spread in most of the organs and 
uncontrolled CD8+ T cells effector functions. High functional virus specific CD8+ T cells 
induced strong immunopathology and resulted in death of mice.  
IFN-I is a crucial pro inflammatory cytokine produced mainly by innate immune cells and 
plays a dual role during viral infection. On the one hand, it limits viral replication because it 
directly induces antiviral molecules in the infected cell108,109,159. Consequently, the absence of 
the interferon-α/β receptor (IFNAR) promotes viral replication and can result in persistence of 
virus102,159. On the other hand, sustained IFN-I signaling induces immunosuppressive 
mechanisms, including the production of interleukin-10 (IL-10) and the expression of 
programmed cell death ligand 1 (PD-L1)112,113,160. IL-10 and PD-L1 are important inhibitors 
of CD8+ T cells and thereby limit the functions of virus-specific CD8+ T cells69,70,161,162. 
Programmed cell death protein 1 (PD-1) is upregulated on almost all activated CD8+ T 
cells114, a finding suggesting that the regulation of its ligand (PD-L1) determines the fate of 
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virus-specific CD8+ T cells. How professional immune cells and/or virus infected cells 
regulate PD-L1 expression during an ongoing infection is not well defined.  
Here with our study we showed viral persistent in absence of adequate IFN-I production, 
means there is a reduced IFN-I signature, lack of immune activation and lack of negative 
immune regulators expression. This type of conditions known to favor for effector functions 
of CD8+ T-cells but with possibilities of immunopathology160. Our results from this study 
conclude that during LCMV infection, CD169+ macrophages prolonged the IFN-I response. 
Prolonged IFN-I responses induced PD-L1 expression in the liver. The absence of CD169+ 
macrophages reduced the antiviral IFN-I activity, but also limited PD-L1 expression. As a 
consequence, mice exhibited overwhelming viral replication in the absence of CD8+ T-cell 
exhaustion, and this replication resulted in strong immunopathology and death of host. 
In next study, we showed that acute infection with LCMV-WE strain lead to induction 
LCMV-specific CD8+ T cells and LCMV-specific antibodies, which finally eliminate virus 
within 10 days and provides long lasting immunological memory. We found that presence of 
LCMV-specific antibodies during systemic recall infection allowed intracellular viral 
replication in CD169+ macrophages of splenic marginal zone but inhibited virus replication in 
peripheral tissues. But presence of LCMV-specific memory CD8+ T cells before infection 
strongly inhibited virus replication in CD169+ macrophages and had limited effect on virus 
replication in peripheral organs. Due this strong inhibition of virus replication in CD169+ 
macrophages, induction of systemic IFN-I was strongly reduced as compare to presence of 
virus-specific antibodies. 
During persistent virus infection with LCMV-Docile, the presence of virus specific 
antibodies before infection led to enhance priming and expansion of virus specific CD8+ T 
cells which resulted in viral control with negligible immunopathology. But presence of virus 
specific memory CD8+ T cells inhibited priming and expansion of endogenous virus specific 
CD8+ T cells that led to virus persistent and immunopathology in mice. The viral clearance in 
presence of virus specific antibodies was found CD8+ T cell dependent because in absence of 
CD8+ T cells, presence of virus specific antibodies could not eradicate viral infection. Virus 
replication in CD169+ macrophages in presence of virus specific antibodies promoted CD8+ T 
cell response and viral control. In absence of CD169+ macrophages or absence of virus 
replication in CD169+ macrophages, the presence of virus specific antibodies failed to induce 
proper CD8+ T cell response which led to develop persistent infection. 
	     88 
						
Viral diseases are big threat for developing world and current vaccination policy of 
World Health Organization (WHO) includes more than 60% of vaccines, which target viral 
diseases163. Most of viral vaccines mediate protective efficacy by inducing virus specific 
antibodies163,164 but often fail to induce virus-specific CD8+ T cells144 . Virus specific 
antibodies are known to clear extracellular virus particles131 but virus specific CD8+ T cells 
are indispensable to kill infected cells, which are reservoir and factory for virus production165. 
Secondary infection after vaccination usually leads to induction of virus specific CD8+ T cells 
and required for virus elimination146,147. The induction of virus specific CD8+ T cells depends 
on innate immune activation in secondary lymphoid organs28,116. So, the efficacy of a 
successful vaccine is at least depending on factors that help innate immune cells activation in 
secondary lymphoid organs during real virus infection. At least from this study we can 
determine that vaccines which are confined to antibody immune response can be a better 
option for targeting viral infections as compare to vaccines that induce only CD8+ T cell 
response. 
From our study, we can conclude that after systemic recall infection during LCMV, the 
presence of virus-specific antibodies allowed intracellular virus replication in CD169+ 
macrophages of splenic marginal zone but cleared virus replication in liver, lung and kidneys. 
After recall infection with the persistent virus strain LCMV-Docile, viral replication in the 
marginal zone was essential for priming and expansion of CD8+ T cells and lead to viral 
elimination. In contrast to specific antibodies, memory CD8+ T cells inhibited viral replication 
in the marginal zone and failed to induce protective immune response, which resulted in 
immunopathology and virus persistent. In conclusion, virus-specific antibodies are better as 
compare to virus specific CD8+ T cells in protecting against persistent prone virus infection. 
As antibodies inhibit virus propagation in periphery but still allow virus replication in spleen 
to induce effective immune response. This describes a novel mechanism of virus specific 
antibodies that provide protection by inhibiting virus in susceptible organs but allowing virus 
replication in a special niche of secondary lymphoid organs. 
From these two studies, we can conclude that CD169+ macrophages present in marginal 
zone of spleen efficiently filter virus particles from circulation, experience virus replication 
that induce IFN-I production and provide sufficient antigens for CD8+ T cell priming during 
primary and secondary infection. These special roles played by marginal zone CD169+ 
macrophages confirm the effective activation of innate and adaptive immune system that 
deliver protective immunity against viral infections. 
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Abbreviations 
 
ADCC   antibody- dependent cell-mediated cytotoxicity 
ALT   alanine aminotransferase 
APC   allophycocyanin 
APC   antigen presenting cell 
BMDM   generated bone marrow-derived macrophage 
Β2M   beta 2 microglobulin 
cDC   conventional or classical dendritic cell 
CFSE   carboxyfluorescein succinimidyl ester 
CFU   colony-forming units 
CTL   cytotoxic T lymphocyte 
CTLA-4   cytotoxic T-lymphocyte-associated protein 4 
DC    dendritic cell 
DT    diphtheria toxin 
DTR   diphtheria toxin receptor 
ELISA   enzyme-linked immunosorbent assay 
FACS   fluorescence-activated cell sorting 
FcR   Fc receptor 
FDC   follicular dendritic cell 
FRC   fibroblastic reticular cell 
GAPDH   glyceraldehyde-3-phosphate dehydrogenase 
GP    glycoprotein 
GzmB   granzyme B 
HBV   hepatitis B virus 
HCV   hepatitis C virus 
HIV   human immunodeficiency virus 
IFN-I   type I interferon 
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IFN-γ   interferon gamma 
IFNAR   interferon alpha/beta receptor 
IFNβ   interferon beta 
Ig    immunoglobulin 
IL    interleukin 
KC    kupffer cell 
LCMV   Lymphocytic choriomeningitis virus 
LCMV-Docile  lymphocytic choriomeningitis virus strain Docile 
LCMV-WE  lymphocytic choriomeningitis virus strain WE 
LDH   lactate dehydrogenase 
LM   listeria monocytogenes 
LN    lymph node 
LPS   lipopolysaccharide 
MACS   magnetic-activated cell sorting 
MALT   mucosal associated lymphoid tissue 
MHC   major histocompatibility complex 
MZ   marginal zone 
NK   natural killer 
NP    nucleoprotein 
NP    nucleoprotein 
PALS   periarteriolar lymphoid sheath 
PAMP   pathogen-associated molecular pattern 
PBS   phosphate buffered saline 
PD-L1   program death ligand 1 
PD1   program death protein 1 
pDC   plasmacytoid dendritic cell 
PFU   plaque-forming units 
PRF1   perforin1 
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PRR   pattern-recognition receptors 
qRT-PCR   quantitative real-time polymerase chain reaction 
r-LCMV   recombinant-LCMV 
RBC   red blood cells 
rLM   recombinant-listeria monocytogenes 
SEM   standard error mean 
SHM   somatic hypermutation 
SLO   secondary lymphoid organ 
TC    cytotoxic T  
TCR   T-cell receptor 
TD    thymus or T cell dependent 
TFH   T follicular helper cell  
TGF-β1   transforming growth factor beta 1 
TH    T helper  
TID   T cell independent  
TIM-3   T-cell immunoglobulin and mucin-domain containing-3  
TLR   toll like receptor 
Treg   T regulatory 
USP18   Ubiquitin-specific peptidase 18 
VSV   vesicular stomatitis virus 
WHO   world health organization 
WT   wild type 
YFP   yellow fluorescent protein 
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